Cluster composition

Functions

Category	Name	IntersectionWithQuery	PValue	GenesInTerm	GenesInQuery	GenesInTermInQuery	ID
GeneOntologyMolecularFunction	myosin binding	MYOC NPC1L1 USH2A CNGA3 IQGAP3 NPHS1 AMPD1 MYO19 ARFGEF1	4.33e-06	85	293	9	GO:0017022
GeneOntologyMolecularFunction	ATP-dependent activity	ATP6V1B2 VWA8 MYO9A MYO9B KIF1B CFTR DDX1 STARD9 SHOC1 ATP11A DHX29 DNHD1 DNAH3 VPS72 DDX60 MYO19 ABCB6 DHX57 DICER1 ENTPD1 ACSL5 KIF1C DNAH11	4.12e-05	614	293	23	GO:0140657
GeneOntologyMolecularFunction	cytoskeletal motor activity	MYO9A MYO9B KIF1B STARD9 DNHD1 DNAH3 MYO19 KIF1C DNAH11	6.17e-05	118	293	9	GO:0003774
GeneOntologyMolecularFunction	extracellular matrix structural constituent	RELN ZP3 SSPOP TINAGL1 ANOS1 HMCN2 AEBP1 FN1 HMCN1 VCAN TNXB	1.09e-04	188	293	11	GO:0005201
GeneOntologyMolecularFunction	caffeine oxidase activity	CYP2C19 CYP2C8 CYP2C9	1.66e-04	8	293	3	GO:0034875
GeneOntologyMolecularFunction	myosin light chain binding	MYOC IQGAP3 MYO19	1.66e-04	8	293	3	GO:0032027
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups, quinone or similar compound as acceptor	CYP2C19 CYP2C8 CYP2C9	1.66e-04	8	293	3	GO:0033695
GeneOntologyMolecularFunction	dynein intermediate chain binding	DNHD1 DNAH3 BAG3 HTT DNAH11	1.95e-04	37	293	5	GO:0045505
GeneOntologyMolecularFunction	(R)-limonene 6-monooxygenase activity	CYP2C19 CYP2C9	2.15e-04	2	293	2	GO:0052741
GeneOntologyMolecularFunction	(S)-limonene 6-monooxygenase activity	CYP2C19 CYP2C9	2.15e-04	2	293	2	GO:0018675
GeneOntologyMolecularFunction	(S)-limonene 7-monooxygenase activity	CYP2C19 CYP2C9	2.15e-04	2	293	2	GO:0018676
GeneOntologyMolecularFunction	limonene monooxygenase activity	CYP2C19 CYP2C9	2.15e-04	2	293	2	GO:0019113
GeneOntologyMolecularFunction	hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds	DDAH1 ADARB1 MTHFD2L AMPD1 AMPD3 NAALAD2 NDST2 ARG2 ASPA	3.12e-04	146	293	9	GO:0016810
GeneOntologyMolecularFunction	estrogen 16-alpha-hydroxylase activity	CYP2C19 CYP2C8 CYP2C9	4.73e-04	11	293	3	GO:0101020
GeneOntologyMolecularFunction	microtubule motor activity	KIF1B STARD9 DNHD1 DNAH3 KIF1C DNAH11	5.66e-04	70	293	6	GO:0003777
GeneOntologyMolecularFunction	cell adhesion molecule binding	CDH23 PAK6 ITGA7 ITGAE ADAM8 NEO1 DHX29 UTRN CNGA3 NPHS1 FN1 ANK3 NRCAM BAG3 NLGN1 TENM4 DCHS1 EMD TNXB CDH11	5.79e-04	599	293	20	GO:0050839
GeneOntologyMolecularFunction	O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase activity	MFNG RFNG	6.38e-04	3	293	2	GO:0033829
GeneOntologyMolecularFunction	adenosine-phosphate deaminase activity	AMPD1 AMPD3	6.38e-04	3	293	2	GO:0047623
GeneOntologyMolecularFunction	AMP deaminase activity	AMPD1 AMPD3	6.38e-04	3	293	2	GO:0003876
GeneOntologyMolecularFunction	cytoskeletal protein binding	CEACAM5 MYO9A MYO9B MYOC KIF1B APC2 CEP350 SAG STARD9 NPC1L1 USH2A UTRN CNGA3 IQGAP3 ESPN NPHS1 AMPD1 SHROOM3 ANK3 NRCAM MYO19 ARFGEF1 SLC4A1 MICALL2 XIRP2 AATF EMD REEP4 HTT KIF1C	8.16e-04	1099	293	30	GO:0008092
GeneOntologyMolecularFunction	ATP hydrolysis activity	VWA8 MYO9B KIF1B CFTR DDX1 SHOC1 ATP11A DHX29 DNAH3 DDX60 MYO19 ABCB6 DHX57 ENTPD1 KIF1C DNAH11	8.60e-04	441	293	16	GO:0016887
GeneOntologyMolecularFunction	retinoic acid 4-hydroxylase activity	CYP2C19 CYP2C8 CYP2C9	1.01e-03	14	293	3	GO:0008401
GeneOntologyMolecularFunction	oxidoreductase activity, acting on CH or CH2 groups	CYP2C19 CYP2C8 CYP2C9	1.25e-03	15	293	3	GO:0016725
GeneOntologyMolecularFunction	arachidonate 11,12-epoxygenase activity	CYP2C19 CYP2C9	1.26e-03	4	293	2	GO:0008405
GeneOntologyMolecularFunction	linoleic acid epoxygenase activity	CYP2C19 CYP2C9	1.26e-03	4	293	2	GO:0071614
GeneOntologyMolecularFunction	group III metabotropic glutamate receptor activity	GRM6 GRM8	1.26e-03	4	293	2	GO:0001642
GeneOntologyBiologicalProcess	neuron development	ARHGAP32 RELN AHI1 MYO9A MYOC CDH23 BCL11A PAK6 CUL7 ADARB1 SLC12A5 BMP4 ANOS1 NEO1 HMCN2 PTPRQ PCDH15 HERC1 CNGA3 PLXNA3 RPGRIP1L FN1 ANK3 NRCAM SMURF1 ARFGEF1 PCDHAC2 NLGN1 ZSWIM6 GBA2 DICER1 TENM4 MICALL2 SLIT3 PLXNA4 SLC4A10 POTEJ TNXB NDRG4 CDH11 HTT SEZ6 SOS1	2.81e-06	1463	288	43	GO:0048666
GeneOntologyBiologicalProcess	cell-cell adhesion	CEACAM5 CDH23 ITGA7 ITGAE ADAM8 ZP3 LRG1 BMP4 NEO1 FAT2 HMCN2 PCDH15 ASTN2 DLG3 PEAR1 NPHS1 ANK3 NRCAM DSG3 PCDHGA4 DTX1 TBX21 PCDHAC2 AMBRA1 NLGN1 SPECC1L CLDN2 SLC4A1 ARG2 TENM4 HMCN1 ENTPD1 DCHS1 TNXB CDH11	3.04e-06	1077	288	35	GO:0098609
GeneOntologyBiologicalProcess	homophilic cell adhesion via plasma membrane adhesion molecules	CEACAM5 CDH23 FAT2 HMCN2 PCDH15 NRCAM DSG3 PCDHGA4 PCDHAC2 HMCN1 DCHS1 CDH11	1.33e-05	187	288	12	GO:0007156
GeneOntologyBiologicalProcess	cell-cell adhesion via plasma-membrane adhesion molecules	CEACAM5 CDH23 FAT2 HMCN2 PCDH15 NRCAM DSG3 PCDHGA4 PCDHAC2 NLGN1 CLDN2 TENM4 HMCN1 DCHS1 CDH11	3.72e-05	313	288	15	GO:0098742
GeneOntologyBiologicalProcess	neuron projection development	ARHGAP32 RELN AHI1 MYO9A MYOC CDH23 BCL11A PAK6 CUL7 ADARB1 SLC12A5 BMP4 ANOS1 NEO1 HMCN2 PCDH15 HERC1 PLXNA3 FN1 ANK3 NRCAM SMURF1 ARFGEF1 PCDHAC2 NLGN1 ZSWIM6 DICER1 MICALL2 SLIT3 PLXNA4 POTEJ TNXB NDRG4 CDH11 SEZ6 SOS1	5.40e-05	1285	288	36	GO:0031175
GeneOntologyBiologicalProcess	growth	ARHGAP32 AHI1 CEACAM5 PDGFRB HELT RPS6KA1 NCBP1 BCL11A PAK6 ZP3 ADARB1 SLC12A5 BMP4 WWC2 CCM2 CHPT1 GPR149 PCDH15 CDC73 TBX20 UNC79 HOXB13 PLXNA3 FN1 NRCAM SMURF1 ZNF416 DICER1 SLC6A3 TENM4 SLIT3 PLXNA4 SLC4A10 NDRG4 SOS1	5.49e-05	1235	288	35	GO:0040007
GeneOntologyBiologicalProcess	morphogenesis of a polarized epithelium	AHI1 MYO9A ASTN2 DLG3 RPGRIP1L DCHS1 JHY	7.13e-05	73	288	7	GO:0001738
GeneOntologyBiologicalProcess	developmental growth	ARHGAP32 PDGFRB HELT BCL11A PAK6 ZP3 ADARB1 SLC12A5 BMP4 WWC2 CCM2 GPR149 PCDH15 TBX20 UNC79 PLXNA3 FN1 NRCAM SMURF1 ZNF416 DICER1 SLC6A3 TENM4 SLIT3 PLXNA4 SLC4A10 NDRG4 SOS1	8.30e-05	911	288	28	GO:0048589
GeneOntologyCellularComponent	non-motile cilium	AHI1 CDH23 PLEKHB1 SAG PCDH15 MERTK USH2A CNGA3 CNGA4 RPGRIP1L VCAN	1.06e-04	196	293	11	GO:0097730
GeneOntologyCellularComponent	photoreceptor cell cilium	AHI1 PLEKHB1 SAG PCDH15 MERTK USH2A CNGA3 RPGRIP1L VCAN	1.54e-04	139	293	9	GO:0097733
GeneOntologyCellularComponent	actin-based cell projection	ATP6V1B2 MYO9B CFTR CDH23 BPIFA1 PTPRQ PCDH15 USH2A UTRN ESPN NLGN1 ZSWIM6 CUBN	1.62e-04	278	293	13	GO:0098858
GeneOntologyCellularComponent	somatodendritic compartment	ARHGAP32 RELN FRMPD4 KIF1B CFTR BCR SLC12A5 NEO1 HMCN2 XRN1 SORCS2 ASTN2 DLG3 BSN USH2A CNGA3 CNGA4 PLK3 STRN3 ANK3 TBX21 SMURF1 NLGN1 GRM6 GRM8 DICER1 SLC6A3 ENTPD1 SLC4A10 HTT SEZ6 KIF1C SOS1	2.62e-04	1228	293	33	GO:0036477
GeneOntologyCellularComponent	9+0 non-motile cilium	AHI1 PLEKHB1 SAG PCDH15 MERTK USH2A CNGA3 RPGRIP1L VCAN	3.17e-04	153	293	9	GO:0097731
GeneOntologyCellularComponent	stereocilium	CDH23 PTPRQ PCDH15 USH2A ESPN ZSWIM6	4.12e-04	69	293	6	GO:0032420
GeneOntologyCellularComponent	extrinsic component of membrane	ATP6V1B2 APC2 CDH23 PIK3C2B BSN CNTFR PLEKHA4 CUBN DCHS1 CTBP1 CDH11	4.24e-04	230	293	11	GO:0019898
GeneOntologyCellularComponent	plasma membrane bounded cell projection cytoplasm	KIF1B EFHB AP3M2 BSN DNHD1 DNAH3 RPGRIP1L AMBRA1 MAPK15 HYDIN HTT KIF1C DNAH11	5.71e-04	317	293	13	GO:0032838
GeneOntologyCellularComponent	cytoplasmic region	KIF1B EFHB AP3M2 BSN DNHD1 DNAH3 RPGRIP1L AMBRA1 MAPK15 CTBP1 HYDIN HTT KIF1C DNAH11	5.99e-04	360	293	14	GO:0099568
GeneOntologyCellularComponent	neuronal cell body	RELN CFTR SLC12A5 NEO1 HMCN2 XRN1 SORCS2 ASTN2 DLG3 BSN USH2A CNGA3 CNGA4 PLK3 STRN3 TBX21 SMURF1 GRM8 SLC6A3 ENTPD1 SLC4A10 HTT SEZ6 SOS1	7.43e-04	835	293	24	GO:0043025
GeneOntologyCellularComponent	stereocilium bundle	CDH23 PTPRQ PCDH15 USH2A ESPN ZSWIM6	8.50e-04	79	293	6	GO:0032421
GeneOntologyCellularComponent	photoreceptor outer segment	AHI1 PLEKHB1 SAG PCDH15 MERTK CNGA3 VCAN	9.71e-04	111	293	7	GO:0001750
GeneOntologyCellularComponent	catenin complex	APC2 CDH23 DCHS1 CDH11	9.98e-04	32	293	4	GO:0016342
GeneOntologyCellularComponent	postsynapse	ARHGAP32 FRMPD4 MYO9A MYO9B KIF1B APC2 BCL11A PAK6 BCR SLC12A5 NEO1 SORCS2 DLG3 BSN LNX1 UTRN STRN3 ANK3 NRCAM NLGN1 GRM6 DICER1 SLC6A3 SLC6A9 SLC4A10 HTT SEZ6	1.17e-03	1018	293	27	GO:0098794
Domain	FN3	TSPOAP1 SPEG IL22RA1 ANOS1 NEO1 ASTN2 MERTK USH2A CNTFR NPHS1 FN1 NRCAM TRIM42 TNXB EPHA1	5.61e-07	199	291	15	PS50853
Domain	FN3_dom	TSPOAP1 SPEG IL22RA1 ANOS1 NEO1 ASTN2 MERTK USH2A CNTFR NPHS1 FN1 NRCAM TRIM42 TNXB EPHA1	1.04e-06	209	291	15	IPR003961
Domain	FN3	TSPOAP1 SPEG ANOS1 NEO1 ASTN2 MERTK USH2A CNTFR NPHS1 FN1 NRCAM TRIM42 TNXB EPHA1	1.28e-06	185	291	14	SM00060
Domain	fn3	TSPOAP1 SPEG ANOS1 NEO1 MERTK USH2A CNTFR NPHS1 FN1 NRCAM TRIM42 TNXB EPHA1	1.59e-06	162	291	13	PF00041
Domain	EGF_1	RELN ADAM8 SSPOP ADAM28 FAT2 HMCN2 ASTN2 USH2A PEAR1 FN1 CUBN TENM4 HMCN1 VCAN SLIT3 TNXB	2.68e-06	255	291	16	PS00022
Domain	EGF_2	RELN ADAM8 SSPOP ADAM28 FAT2 HMCN2 ASTN2 PEAR1 CUBN TENM4 HMCN1 VCAN SLIT3 TNXB EPHA1	1.89e-05	265	291	15	PS01186
Domain	EGF_3	RELN ADAM8 SSPOP ADAM28 FAT2 HMCN2 ASTN2 PEAR1 CUBN TENM4 HMCN1 VCAN SLIT3 TNXB	2.03e-05	235	291	14	PS50026
Domain	-	CEACAM5 PDGFRB TSPOAP1 SPEG MR1 IL22RA1 ANOS1 NEO1 PXDNL VSIG10L ASTN2 MERTK USH2A CNTFR IGSF3 NPHS1 PLXNA3 FN1 NRCAM TRIM42 HMCN1 VCAN PLXNA4 TNXB EPHA1	4.49e-05	663	291	25	2.60.40.10
Domain	Ig-like_fold	CEACAM5 PDGFRB TSPOAP1 SPEG MR1 IL22RA1 ANOS1 NEO1 HMCN2 PXDNL VSIG10L ASTN2 MERTK USH2A CNTFR IGSF3 NPHS1 PLXNA3 FN1 NRCAM TRIM42 HMCN1 VCAN PLXNA4 TNXB EPHA1	4.68e-05	706	291	26	IPR013783
Domain	EGF-like_CS	RELN ADAM8 ADAM28 FAT2 HMCN2 PEAR1 FN1 CUBN TENM4 HMCN1 VCAN SLIT3 TNXB EPHA1	6.41e-05	261	291	14	IPR013032
Domain	Rho_GTPase_activation_prot	ARHGAP32 MYO9A MYO9B BCR IQGAP3 PLXNA3 ARHGAP5 PLXNA4	6.89e-05	88	291	8	IPR008936
Domain	Cadherin_CS	CDH23 FAT2 PCDH15 DSG3 PCDHGA4 PCDHAC2 DCHS1 CDH11	3.08e-04	109	291	8	IPR020894
Domain	IGc2	CEACAM5 PDGFRB SPEG NEO1 HMCN2 PXDNL VSIG10L CNTFR IGSF3 NPHS1 NRCAM HMCN1	3.33e-04	235	291	12	SM00408
Domain	Ig_sub2	CEACAM5 PDGFRB SPEG NEO1 HMCN2 PXDNL VSIG10L CNTFR IGSF3 NPHS1 NRCAM HMCN1	3.33e-04	235	291	12	IPR003598
Domain	CADHERIN_1	CDH23 FAT2 PCDH15 DSG3 PCDHGA4 PCDHAC2 DCHS1 CDH11	3.93e-04	113	291	8	PS00232
Domain	Cadherin	CDH23 FAT2 PCDH15 DSG3 PCDHGA4 PCDHAC2 DCHS1 CDH11	3.93e-04	113	291	8	PF00028
Domain	-	CDH23 FAT2 PCDH15 DSG3 PCDHGA4 PCDHAC2 DCHS1 CDH11	4.17e-04	114	291	8	2.60.40.60
Domain	CADHERIN_2	CDH23 FAT2 PCDH15 DSG3 PCDHGA4 PCDHAC2 DCHS1 CDH11	4.17e-04	114	291	8	PS50268
Domain	CA	CDH23 FAT2 PCDH15 DSG3 PCDHGA4 PCDHAC2 DCHS1 CDH11	4.42e-04	115	291	8	SM00112
Domain	Cadherin-like	CDH23 FAT2 PCDH15 DSG3 PCDHGA4 PCDHAC2 DCHS1 CDH11	4.68e-04	116	291	8	IPR015919
Domain	Cadherin	CDH23 FAT2 PCDH15 DSG3 PCDHGA4 PCDHAC2 DCHS1 CDH11	5.25e-04	118	291	8	IPR002126
Domain	EGF-like_dom	RELN ADAM8 ADAM28 FAT2 HMCN2 PEAR1 CUBN TENM4 HMCN1 VCAN SLIT3 TNXB	5.60e-04	249	291	12	IPR000742
Domain	Fringe	MFNG RFNG	7.18e-04	3	291	2	IPR017374
Domain	AMPD	AMPD1 AMPD3	7.18e-04	3	291	2	IPR006329
Domain	P-loop_NTPase	ATP6V1B2 VWA8 MYO9A MYO9B LSG1 KIF1B CFTR DDX1 STARD9 N4BP2L2 DLG3 DHX29 DNHD1 DNAH3 NOA1 DDX60 MYO19 NDST2 ABCB6 DHX57 DICER1 RABL6 ARHGAP5 HYDIN KIF1C DNAH11	8.14e-04	848	291	26	IPR027417
Domain	Ig_I-set	CEACAM5 PDGFRB SPEG NEO1 HMCN2 PXDNL MERTK NPHS1 NRCAM HMCN1	8.19e-04	190	291	10	IPR013098
Domain	I-set	CEACAM5 PDGFRB SPEG NEO1 HMCN2 PXDNL MERTK NPHS1 NRCAM HMCN1	8.19e-04	190	291	10	PF07679
Domain	-	CUL7 SSPOP GLB1 AEBP1 PCSK7 EPHA1	9.64e-04	73	291	6	2.60.120.260
Domain	WW_DOMAIN_1	FRMPD4 WWC2 UTRN BAG3 SMURF1	1.16e-03	51	291	5	PS01159
Domain	WW_DOMAIN_2	FRMPD4 WWC2 UTRN BAG3 SMURF1	1.16e-03	51	291	5	PS50020
Domain	EGF	RELN ADAM8 ADAM28 FAT2 PEAR1 CUBN TENM4 HMCN1 VCAN SLIT3 TNXB	1.19e-03	235	291	11	SM00181
Domain	ATPase_dyneun-rel_AAA	VWA8 DNAH3 DNAH11	1.20e-03	14	291	3	IPR011704
Domain	MT	DNHD1 DNAH3 DNAH11	1.20e-03	14	291	3	PF12777
Domain	AAA_5	VWA8 DNAH3 DNAH11	1.20e-03	14	291	3	PF07728
Domain	Dynein_HC_stalk	DNHD1 DNAH3 DNAH11	1.20e-03	14	291	3	IPR024743
Domain	Dynein_heavy_dom-2	DNHD1 DNAH3 DNAH11	1.20e-03	14	291	3	IPR013602
Domain	DHC_N2	DNHD1 DNAH3 DNAH11	1.20e-03	14	291	3	PF08393
Domain	WW_dom	FRMPD4 WWC2 UTRN BAG3 SMURF1	1.27e-03	52	291	5	IPR001202
Domain	CLZ	CNGA3 CNGA4	1.42e-03	4	291	2	PF16526
Domain	DNA_pol_B	POLE REV3L	1.42e-03	4	291	2	PF00136
Domain	NIDOGEN_G2	HMCN2 HMCN1	1.42e-03	4	291	2	PS50993
Domain	DNA-dir_DNA_pol_B	POLE REV3L	1.42e-03	4	291	2	IPR006172
Domain	DNA-dir_DNA_pol_B_exonuc	POLE REV3L	1.42e-03	4	291	2	IPR006133
Domain	DNA-dir_DNA_pol_B_multi_dom	POLE REV3L	1.42e-03	4	291	2	IPR006134
Domain	CLZ_dom	CNGA3 CNGA4	1.42e-03	4	291	2	IPR032406
Domain	A/AMP_deam_AS	AMPD1 AMPD3	1.42e-03	4	291	2	IPR006650
Domain	G2_nidogen/fibulin_G2F	HMCN2 HMCN1	1.42e-03	4	291	2	IPR006605
Domain	POLBc	POLE REV3L	1.42e-03	4	291	2	SM00486
Domain	G2F	HMCN2 HMCN1	1.42e-03	4	291	2	PF07474
Domain	GFP	HMCN2 HMCN1	1.42e-03	4	291	2	IPR009017
Domain	DNA_pol_B_exo1	POLE REV3L	1.42e-03	4	291	2	PF03104
Domain	DHC_fam	DNHD1 DNAH3 DNAH11	1.48e-03	15	291	3	IPR026983
Domain	Dynein_heavy	DNHD1 DNAH3 DNAH11	1.48e-03	15	291	3	PF03028
Domain	Dynein_heavy_dom	DNHD1 DNAH3 DNAH11	1.48e-03	15	291	3	IPR004273
Pubmed	A dual-activity topoisomerase complex regulates mRNA translation and turnover.	STK36 TPRA1 ACACA VWA8 MYO9B SPEG SREBF1 ATG2A BCR TINAGL1 BMP4 SARS2 PIK3C2B A4GALT TIGD3 HERC1 IQGAP3 PLK3 HOXB13 IGSF3 PLXNA3 SHROOM3 POLE RTTN KSR2 AMBRA1 REV3L GBA2 RABL6 NCOR2 MAPKBP1 HTT	1.99e-09	1105	296	32	35748872
Pubmed	Identifications of novel host cell factors that interact with the receptor-binding domain of the SARS-CoV-2 spike protein.	RPN2 LSG1 RPS6KA1 NOL6 SREBF1 BCR DDX1 GLB1 XRN1 IQGAP3 RNF31 NOA1 POLE MYO19 ANGEL1 AMBRA1 DHX57 COLGALT1 DICER1 ASH2L DENND3 GTF3C1 DDHD1	1.15e-08	650	296	23	38777146
Pubmed	Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.	FRMPD4 TSPOAP1 SPEG KIF1B BCL11A SLC12A5 UBR5 STARD9 RAB3GAP2 DLG3 NRCAM SMURF1 NLGN1 ZSWIM6 VIRMA EPG5 TENM4 MAPKBP1	1.69e-08	407	296	18	12693553
Pubmed	KCTD13-mediated ubiquitination and degradation of GluN1 regulates excitatory synaptic transmission and seizure susceptibility.	ATP6V1B2 ARHGAP32 DDAH1 MYO9A KIF1B BCL11A BCR DDX1 SLC12A5 PTPRA PURB XRN1 SORCS2 DLG3 BSN DHX29 UTRN VARS1 STRN3 FN1 ANK3 NRCAM SMURF1 DHX57 SPECC1L VIRMA SLC4A1 ARHGAP5 TENM4 VCAN SYNGR1 PLXNA4 SLC4A10 CTBP1 DNAH11	2.45e-08	1431	296	35	37142655
Pubmed	Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.	ATP6V1B2 RELN PDGFRB KIF1B APC2 TRPS1 NCBP1 QRICH1 GNPTG ADARB1 PLEKHB1 FRMD4B CEP350 SARS2 PTPRA N4BP2L2 ASTN2 MERTK LNX1 UTRN VARS1 FN1 VPS72 ANK3 NRCAM REV3L ARG2 ARHGAP5 RNF123 ASPA CTBP1 SOS1	6.80e-08	1285	296	32	35914814
Pubmed	Defining the proximal interaction networks of Arf GTPases reveals a mechanism for the regulation of PLD1 and PI4KB.	ACACA LSG1 VPS13C KIF1B NOL6 ZNF318 TASOR2 CEP350 NEO1 UBR5 XRN1 DLG3 IGSF3 SHROOM3 RPGRIP1L FN1 ANK3 ANGEL1 ARFGEF1 SPECC1L SFXN1 RABL6 CTBP1 EMD	7.07e-08	777	296	24	35844135
Pubmed	Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.	TPRA1 ACACA MYO9A VPS13C KIF1B TRPS1 ADGRG1 BCR ZP3 ADARB1 SSPOP TASOR2 ITFG1 SHC2 NUP210 ASTN2 ATP11A ZSWIM4 MMP16 UTRN ESPN CYP4V2 SHROOM3 ANK3 KSR2 SMURF1 ZSWIM6 SFXN1 NCOR2 GTF3C1 ENTPD1 PRKAG1 CTBP1 HTT	1.98e-07	1489	296	34	28611215
Pubmed	CYP2C8, CYP2C9, and CYP2C19 Characterization Using Next-Generation Sequencing and Haplotype Analysis: A GeT-RM Collaborative Project.	CYP2C19 CYP2C8 CYP2C9	6.10e-07	3	296	3	35134542
Pubmed	Polymorphisms of CYP2C8, CYP2C9 and CYP2C19 and risk of coronary heart disease in Russian population.	CYP2C19 CYP2C8 CYP2C9	6.10e-07	3	296	3	28687336
Pubmed	Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians.	CYP2C19 CYP2C8 CYP2C9	6.10e-07	3	296	3	21173785
Pubmed	Genetic polymorphisms of CYP2C8, CYP2C9 and CYP2C19 in Ecuadorian Mestizo and Spaniard populations: a comparative study.	CYP2C19 CYP2C8 CYP2C9	6.10e-07	3	296	3	24430292
Pubmed	Genetic Polymorphisms and in Vitro Functional Characterization of CYP2C8, CYP2C9, and CYP2C19 Allelic Variants.	CYP2C19 CYP2C8 CYP2C9	6.10e-07	3	296	3	27803446
Pubmed	Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population.	CYP2C19 CYP2C8 CYP2C9	6.10e-07	3	296	3	19954515
Pubmed	Distribution of CYP2C polymorphisms in an Amerindian population of Brazil.	CYP2C19 CYP2C8 CYP2C9	6.10e-07	3	296	3	21977947
Pubmed	Structural characterization of human cytochrome P450 2C19: active site differences between P450s 2C8, 2C9, and 2C19.	CYP2C19 CYP2C8 CYP2C9	6.10e-07	3	296	3	23118231
Pubmed	A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24.	CYP2C19 CYP2C8 CYP2C9	6.10e-07	3	296	3	8530044
Pubmed	Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations.	CYP2C19 CYP2C8 CYP2C9	6.10e-07	3	296	3	20665013
Pubmed	The RNA-mediated estrogen receptor α interactome of hormone-dependent human breast cancer cell nuclei.	ATP6V1B2 CEACAM5 LSG1 TRPS1 NOL6 ADGRG1 ZNF318 PHC3 PURB XRN1 DLG3 HEATR5B DHX29 UTRN IQGAP3 VARS1 STRN3 SHROOM3 VPS72 NOA1 POLR2B ABCB6 DHX57 SPECC1L VIRMA DICER1 ASH2L RIOX2 MICALL2 AATF CTBP1 REEP4 EDRF1	6.66e-07	1497	296	33	31527615
Pubmed	Cullin 1 (CUL1) Promotes Primary Ciliogenesis through the Induction of Ubiquitin-Proteasome-Dependent Dvl2 Degradation.	ACACA VPS13C CDH23 FAT2 DTX1 REV3L DENND3 HMCN1 HTT DNAH11	7.93e-07	152	296	10	34299191
Pubmed	Simultaneous mutation detection in 90 retinal disease genes in multiple patients using a custom-designed 300-kb retinal resequencing chip.	MYOC CDH23 SAG PCDH15 MERTK USH2A CNGA3 GRM6	8.18e-07	87	296	8	20801516
Pubmed	Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.	STK36 ARHGAP32 TSPOAP1 APC2 ATG2A TASOR2 PHC3 AEBP1 BSN SHROOM3 ANK3 DTX1 TEX14 NCOR2 XIRP2 SOS1	1.06e-06	430	296	16	35044719
Pubmed	A central chaperone-like role for 14-3-3 proteins in human cells.	ARHGAP32 ACACA MYO9A LSG1 KIF1B PAK6 DYRK4 BCR DDX1 CEP350 WWC2 PIK3C2B STARD9 RAB3GAP2 XRN1 UTRN SHROOM3 BAG3 PTPN21 VIRMA REEP4 EDRF1 KIF1C	1.63e-06	861	296	23	36931259
Pubmed	Inhibition of RIF1 by SCAI Allows BRCA1-Mediated Repair.	BCR BSN POLR2B REV3L	2.41e-06	12	296	4	28700933
Pubmed	Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.	CYP2C19 CYP2C8 CYP2C9	2.43e-06	4	296	3	19706858
Pubmed	Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.	CYP2C19 CYP2C8 CYP2C9	2.43e-06	4	296	3	16025294
Pubmed	Biochemistry and molecular biology of the human CYP2C subfamily.	CYP2C19 CYP2C8 CYP2C9	2.43e-06	4	296	3	7704034
Pubmed	BIG1 is a binding partner of myosin IXb and regulates its Rho-GTPase activating protein activity.	MYO9A MYO9B ARFGEF1	2.43e-06	4	296	3	15644318
Pubmed	Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.	CYP2C19 CYP2C8 CYP2C9	2.43e-06	4	296	3	28990182
Pubmed	Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily.	CYP2C19 CYP2C8 CYP2C9	2.43e-06	4	296	3	2009263
Pubmed	Genetic variation in the CYP2C monooxygenase enzyme subfamily shows no association with longevity in a German population.	CYP2C19 CYP2C8 CYP2C9	2.43e-06	4	296	3	21798861
Pubmed	Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.	CYP2C19 CYP2C8 CYP2C9	2.43e-06	4	296	3	23755828
Pubmed	Identification of new ciliary signaling pathways in the brain and insights into neurological disorders.	SLCO3A1 PAK6 PLEKHB1 SLC12A5 NEO1 PTPRA AP3M2 ASTN2 PCDHGA4 NLGN1 SLC4A1 SFXN1 SLC6A9 TENM4 SLC4A10	2.45e-06	405	296	15	38187761
Pubmed	TNF-α inhibits glucocorticoid receptor-induced gene expression by reshaping the GR nuclear cofactor profile.	ARHGAP32 TRPS1 NOL6 CEP350 BSN IGSF3 TCAF2 AMPD1 POLE MRPL28 REV3L VIRMA ASH2L NCOR2 RNF123 DDHD1 AATF POTEJ DNAH11	2.87e-06	638	296	19	31182584
Pubmed	Spatiotemporal profile of postsynaptic interactomes integrates components of complex brain disorders.	ARHGAP32 LSG1 APC2 ZNF318 BCL11A BCR SLC12A5 UBR5 PURB DLG3 CDC73 BSN UNC79 STRN3 SHROOM3 ANK3 NRCAM KSR2 SPECC1L VIRMA NCOR2 DCHS1 CTBP1 CDH11	3.17e-06	963	296	24	28671696
Pubmed	TRIM65 regulates microRNA activity by ubiquitination of TNRC6.	MYO9B LSG1 NOL6 NCBP1 ADARB1 GLB1 PURB CDC73 IQGAP3 NOA1 POLR2B DHX57 DICER1 AATF	3.45e-06	364	296	14	24778252
Pubmed	Functional proteomics establishes the interaction of SIRT7 with chromatin remodeling complexes and expands its role in regulation of RNA polymerase I transcription.	ACACA RPN2 NOL6 WDR46 NCBP1 ZNF318 CUL7 TASOR2 UBR5 NUP210 XRN1 UTRN FN1 POLE DHX57 VIRMA DICER1 GTF3C1 AATF	4.01e-06	653	296	19	22586326
Pubmed	Systematic bromodomain protein screens identify homologous recombination and R-loop suppression pathways involved in genome integrity.	TRIM4 VWA8 LSG1 ENTR1 TRPS1 ZNF318 BCL11A CUL7 BCR SALL2 HMCN2 UBR5 XRN1 VPS72 RNF31 POLR2B ANGEL1 AMBRA1 REV3L DICER1 SLC4A1 ARG2 NCOR2 METTL13 LRRC8B SOS1	4.12e-06	1116	296	26	31753913
Pubmed	Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy.	CYP2C19 CYP2C8 CYP2C9	6.03e-06	5	296	3	19415824
Pubmed	Prevalence of CYP450 gene variations in patients with type 2 diabetes.	CYP2C19 CYP2C8 CYP2C9	6.03e-06	5	296	3	20857895
Pubmed	Large-scale cDNA transfection screening for genes related to cancer development and progression.	WDR46 GNPTG TINAGL1 CCM2 ESPN CLDN2 RNF123 REEP4	6.32e-06	114	296	8	15498874
Pubmed	LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy.	ACACA RPN2 MYO9B NUP210 XRN1 IQGAP3 DDX60 DHX57 SPECC1L DICER1	1.01e-05	202	296	10	33005030
Pubmed	Proteomic and Biochemical Comparison of the Cellular Interaction Partners of Human VPS33A and VPS33B.	ARHGAP32 LSG1 ENTR1 BCL11A BCR CEP350 RPGRIP1L ANK3 POLE RABL6 KIF1C	1.16e-05	251	296	11	29778605
Pubmed	Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population.	CYP2C19 CYP2C8 CYP2C9	1.20e-05	6	296	3	17635176
Pubmed	Large-scale identification of c-MYC-associated proteins using a combined TAP/MudPIT approach.	MYO9A RPN2 MYO9B BCR DDX1 XRN1 IQGAP3 POLE POLR2B GTF3C1	1.48e-05	211	296	10	17314511
Pubmed	Overlapping Activities of Two Neuronal Splicing Factors Switch the GABA Effect from Excitatory to Inhibitory by Regulating REST.	AHI1 VPS13C KIF1B SLC12A5 CHPT1 ANK3 NRCAM SLC4A10	1.48e-05	128	296	8	30995482
Pubmed	Gain of Additional BIRC3 Protein Functions through 3'-UTR-Mediated Protein Complex Formation.	ACACA TRIM4 PDGFRB RPN2 LSG1 VPS13C NOL6 WDR46 NCBP1 DDX1 STARD9 RAB3GAP2 NUP210 CDC73 BSN DHX29 IQGAP3 VARS1 DNHD1 POLE POLR2B COLGALT1 DICER1 SFXN1 RIOX2 METTL13 MAPK15 GTF3C1 EMD	1.49e-05	1425	296	29	30948266
Pubmed	A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease.	CYP2C8 CYP2C9 CDH23 ADAM8 CSGALNACT2 PCDH15 ANK3 FAM13C BAG3 NDST2 XPNPEP1 CUBN ENTPD1 ACSL5	1.52e-05	415	296	14	16385451
Pubmed	The deubiquitinase TRABID stabilizes the K29/K48-specific E3 ubiquitin ligase HECTD1.	ACACA CUL7 GLB1 XRN1 CDC73 VARS1 STRN3 SPECC1L DICER1 PRKAG1	1.54e-05	212	296	10	33853758
Pubmed	Proximity-dependent biotin identification (BioID) reveals a dynamic LSD1-CoREST interactome during embryonic stem cell differentiation.	ACACA TRPS1 ZNF318 BCR PHC3 SALL2 UBR5 RAB3GAP2 XRN1 UTRN BAG3 NCOR2 GTF3C1 CTBP1	1.64e-05	418	296	14	34709266
Pubmed	Cytoplasmic Metadherin (MTDH) provides survival advantage under conditions of stress by acting as RNA-binding protein.	CUL7 TINAGL1 NEO1 PURB NUP210 CYP4V2 PLXNA3 FN1 CLDN2 RNF123	1.67e-05	214	296	10	22199357
Pubmed	Proteomics analysis of cardiac extracellular matrix remodeling in a porcine model of ischemia/reperfusion injury.	SSPOP TINAGL1 FN1 HMCN1 VCAN TNXB	1.79e-05	64	296	6	22261194
Pubmed	Biochemical characterization of native Usher protein complexes from a vesicular subfraction of tracheal epithelial cells.	CDH23 PCDH15 USH2A	2.08e-05	7	296	3	20058854
Pubmed	Cochlear developmental defect and background-dependent hearing thresholds in the Jackson circler (jc) mutant mouse.	CDH23 PCDH15 ESPN	2.08e-05	7	296	3	16962269
Pubmed	Construction of long-transcript enriched cDNA libraries from submicrogram amounts of total RNAs by a universal PCR amplification method.	AHI1 ZNF318 PHC3 WWC2 PURB N4BP2L2 ATP11A HERC1 UTRN AEN FN1 ANK3 POLR2B ANGEL1 SMURF1 IRGQ COLGALT1 CUBN ASH2L ARHGAP5 ZNF750 DDHD1 VCAN AATF	2.23e-05	1084	296	24	11544199
Pubmed	Mouse screen reveals multiple new genes underlying mouse and human hearing loss.	DDAH1 MYO9A RPN2 INPP1 CDH23 IL22RA1 PTH2R SAG DLG3 ATP11A HERC1 CNTFR PEAR1 ESPN AMPD3 RPGRIP1L VPS72 GATC ABCB6 XPNPEP1 GRM8 GBA2 VIRMA MOSPD1 DDHD1 ENTPD1	2.62e-05	1242	296	26	30973865
Pubmed	Network organization of the human autophagy system.	ACACA RPN2 ATG2A PTPRA RAB3GAP2 UTRN VARS1 AMBRA1 IRGQ SFXN1 GTF3C1 XIRP2 PRKAG1 EMD	2.68e-05	437	296	14	20562859
Pubmed	Impaired plasma membrane localization of ubiquitin ligase complex underlies 3-M syndrome development.	ARHGAP32 DDAH1 RPN2 TRPS1 CUL7 TASOR2 GLB1 PURB DHX29 SHROOM3 C2orf88 RTTN DHX57 POTEJ KIF1C	2.70e-05	496	296	15	31343991
Pubmed	Reciprocal interaction between SIRT6 and APC/C regulates genomic stability.	ACACA LSG1 NOL6 ZNF318 UBR5 NUP210 DHX29 VPS72 POLR2B AMBRA1 DICER1 ASH2L GTF3C1 AATF	2.88e-05	440	296	14	34244565
Pubmed	Microarray-based mutation analysis of 183 Spanish families with Usher syndrome.	CDH23 PCDH15 USH2A	3.31e-05	8	296	3	19683999
Pubmed	UMD-USHbases: a comprehensive set of databases to record and analyse pathogenic mutations and unclassified variants in seven Usher syndrome causing genes.	CDH23 PCDH15 USH2A	3.31e-05	8	296	3	18484607
Pubmed	Molecular basis of human Usher syndrome: deciphering the meshes of the Usher protein network provides insights into the pathomechanisms of the Usher disease.	CDH23 PCDH15 USH2A	3.31e-05	8	296	3	16545802
Pubmed	Identification of motif-based interactions between SARS-CoV-2 protein domains and human peptide ligands pinpoint antiviral targets.	QRICH1 STARD9 NPC1L1 DLG3 BSN DNAH3 PTF1A FAM220A XIRP2 DNAH11	3.46e-05	233	296	10	37704626
Pubmed	Phenotypic and Interaction Profiling of the Human Phosphatases Identifies Diverse Mitotic Regulators.	ATP6V1B2 ARHGAP32 RPN2 ENTR1 TRPS1 NCBP1 CUL7 CEP350 WWC2 PTPRA NUP210 HERC1 UTRN RPGRIP1L ANK3 POLR2B BAG3 PTPN21 COLGALT1 ARHGAP5 NCOR2 AATF EMD	3.85e-05	1049	296	23	27880917
Pubmed	Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function.	ACACA MYO9A MYO9B LSG1 NOL6 WDR46 DDX1 UBR5 XRN1 DHX29 UTRN VARS1 FN1 RNF31 POLE MYO19 POLR2B BAG3 AMBRA1 DHX57 COLGALT1 SFXN1 NCOR2 METTL13 GTF3C1 AATF EMD	4.16e-05	1353	296	27	29467282
Pubmed	Characterization of the zinc-induced Shank3 interactome of mouse synaptosome.	CDH23 TASOR2 SLC12A5 PURB SFXN1 XIRP2 DDHD1	4.28e-05	109	296	7	29111324
Pubmed	Neuron-specific protein network mapping of autism risk genes identifies shared biological mechanisms and disease-relevant pathologies.	ARHGAP32 FRMPD4 ACACA VWA8 TSPOAP1 BCR NEO1 PURB RAB3GAP2 XRN1 DLG3 BSN DHX29 VARS1 IGSF3 STRN3 ANK3 NRCAM SFXN1 TENM4 SYNGR1 SLC4A10 EMD NDRG4	4.88e-05	1139	296	24	36417873
Pubmed	Genome-wide CRISPR screens identify novel regulators of wild-type and mutant p53 stability.	MYO9A MYO9B ENTR1 KIF1B ZNF318 CUL7 BCR DDX1 SALL2 UBR5 PIK3C2B BSN RPGRIP1L VPS72 NCOR2 POTEJ	5.18e-05	588	296	16	38580884
Pubmed	Prediction of the coding sequences of unidentified human genes. XVI. The complete sequences of 150 new cDNA clones from brain which code for large proteins in vitro.	VPS13C SPEG STARD9 SORCS2 HEATR5B UNC79 VIRMA TENM4	5.33e-05	153	296	8	10718198
Pubmed	Functional proteomics mapping of a human signaling pathway.	QRICH1 TINAGL1 BMP4 UBR5 HERC1 MERTK UHRF2 UTRN FN1 ANK3 SMURF1 ASH2L EPG5 ARHGAP5 NCOR2 RNF123	5.49e-05	591	296	16	15231748
Pubmed	Massively parallel DNA sequencing facilitates diagnosis of patients with Usher syndrome type 1.	CDH23 PCDH15 USH2A	7.01e-05	10	296	3	24618850
Pubmed	Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.	CYP2C19 CYP2C8 CYP2C9	7.01e-05	10	296	3	20602612
Pubmed	Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease.	CYP2C19 CYP2C8 CYP2C9	7.01e-05	10	296	3	19651758
Pubmed	Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins.	CYP2C19 CYP2C9 SREBF1	7.01e-05	10	296	3	20235787
Pubmed	Usher protein functions in hair cells and photoreceptors.	CDH23 PCDH15 USH2A	7.01e-05	10	296	3	24239741
Pubmed	E3 ubiquitin ligase RNF123 targets lamin B1 and lamin-binding proteins.	ACACA VPS13C NCBP1 ITGAE SSPOP UTRN DNAH3 ZNF775 FN1 MYO19 REV3L SFXN1 RIOX2 ARHGAP5 RNF123 GTF3C1 PLXNA4 EMD	7.02e-05	736	296	18	29676528
Pubmed	AEBP1 promotes papillary thyroid cancer progression by activating BMP4 signaling.	BMP4 AEBP1	7.22e-05	2	296	2	38237535
Pubmed	Effect of gender and CYP2C9 and CYP2C8 polymorphisms on the pharmacokinetics of ibuprofen enantiomers.	CYP2C8 CYP2C9	7.22e-05	2	296	2	26122864
Pubmed	Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.	SLC6A3 HTT	7.22e-05	2	296	2	17065224
Pubmed	Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.	CYP2C8 CYP2C9	7.22e-05	2	296	2	12435384
Pubmed	Important amino acid residues that confer CYP2C19 selective activity to CYP2C9.	CYP2C19 CYP2C9	7.22e-05	2	296	2	18511451
Pubmed	Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers.	CYP2C8 CYP2C9	7.22e-05	2	296	2	18694831
Pubmed	Deregulation of versican and elastin binding protein in solar elastosis.	GLB1 VCAN	7.22e-05	2	296	2	18704747
Pubmed	Fibronectin fragments and the cleaving enzyme ADAM-8 in the degenerative human intervertebral disc.	ADAM8 FN1	7.22e-05	2	296	2	25010013
Pubmed	Using thermal scanning assays to test protein-protein interactions of inner-ear cadherins.	CDH23 PCDH15	7.22e-05	2	296	2	29261728
Pubmed	The contribution of CYP2C gene subfamily involved in epoxygenase pathway of arachidonic acids metabolism to hypertension susceptibility in Russian population.	CYP2C19 CYP2C8	7.22e-05	2	296	2	28513222
Pubmed	Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms.	CYP2C19 CYP2C9	7.22e-05	2	296	2	15385837
Pubmed	[Effect of original and generic clopidogrel on prognosis in relation to different gene polymorphisms].	CYP2C19 CYP2C9	7.22e-05	2	296	2	25518510
Pubmed	Time serial transcriptome reveals Cyp2c29 as a key gene in hepatocellular carcinoma development.	CYP2C19 CYP2C9	7.22e-05	2	296	2	32587777
Pubmed	CYP2C9 (2&3) and CYP2C19 (2&3) polymorphisms among children with nonlesional epilepsy: a single-center study.	CYP2C19 CYP2C9	7.22e-05	2	296	2	32683556
Pubmed	Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients.	CYP2C19 CYP2C9	7.22e-05	2	296	2	15855721
Pubmed	Mouse liver CYP2C39 is a novel retinoic acid 4-hydroxylase. Its down-regulation offers a molecular basis for liver retinoid accumulation and fibrosis in aryl hydrocarbon receptor-null mice.	CYP2C19 CYP2C9	7.22e-05	2	296	2	14623888
Pubmed	Allelic hierarchy of CDH23 mutations causing non-syndromic deafness DFNB12 or Usher syndrome USH1D in compound heterozygotes.	CDH23 PCDH15	7.22e-05	2	296	2	21940737
Pubmed	A heart segmental defect in the anterior-posterior axis of a transgenic mutant mouse.	FN1 VCAN	7.22e-05	2	296	2	9188753
Pubmed	Core-shell PLGA/collagen nanofibers loaded with recombinant FN/CDHs as bone tissue engineering scaffolds.	FN1 CDH11	7.22e-05	2	296	2	24844413
Pubmed	VIRMA promotes the progression of head and neck squamous cell carcinoma by regulating UBR5 mRNA and m6A levels.	UBR5 VIRMA	7.22e-05	2	296	2	38577917
Pubmed	Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing on-chip capillary electrophoresis.	CYP2C19 CYP2C9	7.22e-05	2	296	2	22589111
Pubmed	Digenic inheritance of deafness caused by mutations in genes encoding cadherin 23 and protocadherin 15 in mice and humans.	CDH23 PCDH15	7.22e-05	2	296	2	15537665
Pubmed	CYP2C9 and CYP2C19 genetic polymorphisms: frequencies in the south Indian population.	CYP2C19 CYP2C9	7.22e-05	2	296	2	15660966
Pubmed	Analysis of the Potential Association of Drug-Metabolizing Enzymes CYP2C93 and CYP2C193 Gene Variations With Type 2 Diabetes: A Case-Control Study.	CYP2C19 CYP2C9	7.22e-05	2	296	2	33115391
Pubmed	Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.	CYP2C19 CYP2C9	7.22e-05	2	296	2	17562299
Interaction	YWHAQ interactions	ARHGAP32 ACACA TRIM4 MYO9A SPEG RPS6KA1 KIF1B CFTR PAK6 CUL7 BCR DDX1 CEP350 WWC2 PIK3C2B STARD9 CDC73 MERTK LNX1 UNC79 VARS1 SHROOM3 RPGRIP1L FN1 TRIM42 BAG3 KSR2 PLEKHA4 SMURF1 SPECC1L VIRMA CRY2 EMD REEP4 HTT KIF1C	7.17e-06	1118	294	36	int:YWHAQ
Interaction	PDE3B interactions	CYP2C9 PDGFRB RPN2 LNX1 PLEKHA4 PCDHAC2 VIRMA RNF123 LRRC8B EMD	7.25e-06	115	294	10	int:PDE3B
Interaction	B4GALT2 interactions	ARHGAP32 TRIM4 ZNF318 QRICH1 N4BP2L2 IQGAP3 RNF31 POLE NCOR2 DCHS1	9.83e-06	119	294	10	int:B4GALT2
Interaction	DQX1 interactions	MYO9A MYO9B CFTR AMBRA1 RNF123	1.07e-05	21	294	5	int:DQX1
Cytoband	7p13	CCM2 AEBP1 PURB NPC1L1	1.17e-04	39	296	4	7p13
GeneFamily	Fibronectin type III domain containing	TSPOAP1 ANOS1 NEO1 PTPRQ ASTN2 MERTK USH2A CNTFR NPHS1 FN1 NRCAM TRIM42 TNXB EPHA1	3.53e-09	160	203	14	555
GeneFamily	Cadherin related	CDH23 FAT2 PCDH15 DCHS1	3.27e-05	17	203	4	24
GeneFamily	Immunoglobulin like domain containing	CEACAM5 PDGFRB NEO1 HMCN2 VSIG10L MERTK CNTFR IGSF3 NPHS1 NRCAM	6.71e-05	193	203	10	594
GeneFamily	Blood group antigens\|CD molecules\|I-set domain containing\|Immunoglobulin like domain containing	CEACAM5 PDGFRB SPEG NEO1 HMCN2 PXDNL MERTK NRCAM HMCN1	8.71e-05	161	203	9	593
GeneFamily	Myosins, class IX	MYO9A MYO9B	1.25e-04	2	203	2	1103
GeneFamily	Adenosine deaminase family	AMPD1 AMPD3	1.83e-03	6	203	2	1302
Coexpression	NABA_ECM_GLYCOPROTEINS	RELN ZP3 SSPOP LRG1 TINAGL1 ANOS1 HMCN2 AEBP1 PXDNL USH2A FN1 HMCN1 SLIT3 TNXB	5.43e-08	196	295	14	M3008
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HGABA	RELN FRMPD4 TSPOAP1 SPEG APC2 SLCO3A1 ZNF318 BCL11A SSPOP FRMD4B SLC12A5 FAT2 BLID DLG3 HERC1 BSN UNC79 IGSF3 PLXNA3 ANK3 KSR2 SMURF1 ARFGEF1 NLGN1 IRGQ REV3L DICER1 SLC4A1 PIEZO2 VCAN PLXNA4 FAM217B HYDIN NDRG4	1.24e-07	1106	295	34	M39071
Coexpression	NABA_CORE_MATRISOME	RELN ZP3 SSPOP LRG1 TINAGL1 ANOS1 HMCN2 AEBP1 PXDNL USH2A FN1 HMCN1 VCAN SLIT3 TNXB	6.07e-07	275	295	15	M5884
Coexpression	HE_LIM_SUN_FETAL_LUNG_C1_SMG_CELL	TRPS1 MR1 SLCO3A1 ADGRG1 ATG2A ADAM28 PTH2R PIK3IP1 FAT2 SHC2 AEBP1 LNX1 DAGLB CYP4V2 AEN IQCH PLAAT4 RTTN ZNF750 MICALL2 VCAN SLIT3 KCTD14 RINL	8.64e-06	775	295	24	M45713
Coexpression	NABA_ECM_GLYCOPROTEINS	RELN ZP3 SSPOP LRG1 TINAGL1 HMCN2 AEBP1 FN1 HMCN1 SLIT3 TNXB	1.17e-05	191	295	11	MM17059
Coexpression	GSE29618_BCELL_VS_PDC_DAY7_FLU_VACCINE_UP	ZNF318 ADAM8 ADAM28 PIK3IP1 UBR5 PIK3C2B AEN AMPD3 PLAAT4 DENND3 ENTPD1	1.36e-05	194	295	11	M4958
Coexpression	DEBIASI_APOPTOSIS_BY_REOVIRUS_INFECTION_DN	TSPOAP1 MYO9B BCL11A ATG2A ITGA7 GLB1 NUP210 IGSF3 ABCB6 DICER1 METTL13 VCAN EDRF1	1.66e-05	276	295	13	M3063
Coexpression	GSE17721_CPG_VS_GARDIQUIMOD_8H_BMDC_DN	TRPS1 ZNF318 UBR5 ESPN AMPD3 BAG3 ARFGEF1 DICER1 SFXN1 RABL6 NDRG4	1.80e-05	200	295	11	M3893
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HNBML5	TSPOAP1 SPEG APC2 SLCO3A1 BCL11A SLC12A5 DLG3 HERC1 BSN USH2A PLXNA3 ANK3 KSR2 IRGQ DICER1 PLXNA4 NDRG4	2.39e-05	465	295	17	M39066
Coexpression	MANNO_MIDBRAIN_NEUROTYPES_HNBGABA	FRMPD4 SLCO3A1 FRMD4B SLC12A5 ANOS1 TIGD3 BSN UNC79 ANK3 KSR2 NLGN1 IRGQ REV3L GRM8 DICER1 DENND3 SLC4A1 TENM4 PLXNA4 NDRG4 SEZ6	5.35e-05	703	295	21	M39070
Coexpression	GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN	RELN SPEG KIF1B MR1 ITGA7 FRMD4B PIK3IP1 NEO1 CHPT1 AEBP1 RAB3GAP2 XRN1 PLK3 PLXNA3 ANK3 NRCAM FAM13C RTTN SMURF1 PMEL CUBN ARHGAP5 DDHD1 SYNGR1 ASPA LRRC8B NDRG4 HTT	5.59e-05	1102	295	28	M2369
Coexpression	HE_LIM_SUN_FETAL_LUNG_C7_MID_SCHWANN_CELL	RELN FRMD4B TINAGL1 STARD9 UTRN ESPN FN1 ANK3 PLEKHA4 HPDL MICALL2 ASPA	5.73e-05	268	295	12	M45796
Coexpression	NABA_CORE_MATRISOME	RELN ZP3 SSPOP LRG1 TINAGL1 HMCN2 AEBP1 FN1 HMCN1 VCAN SLIT3 TNXB	6.15e-05	270	295	12	MM17057
Coexpression	GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN	RELN SPEG KIF1B MR1 ITGA7 FRMD4B PIK3IP1 NEO1 CHPT1 AEBP1 RAB3GAP2 XRN1 PLK3 PLXNA3 ANK3 NRCAM FAM13C RTTN SMURF1 PMEL CUBN ARHGAP5 DDHD1 SYNGR1 ASPA LRRC8B NDRG4 HTT	7.85e-05	1124	295	28	MM1070
Coexpression	GSE16385_MONOCYTE_VS_12H_ROSIGLITAZONE_IFNG_TNF_TREATED_MACROPHAGE_UP	KIF1B WDR46 PAK6 ITGAE ADAM8 DAGLB RNF31 TBX21 GBA2 UBE2T	8.84e-05	198	295	10	M7902
Coexpression	GSE41978_WT_VS_ID2_KO_KLRG1_LOW_EFFECTOR_CD8_TCELL_DN	RPN2 CFTR BCR SORCS2 MERTK PLK3 ESPN DTX1 XPNPEP1 CUBN	9.61e-05	200	295	10	M9549
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	STK36 RELN FRMPD4 CFTR SSPOP PTPRQ PCDH15 USH2A UNC79 NRCAM PIEZO2 TENM4 HMCN1 XIRP2 HYDIN DNAH11	1.28e-13	184	296	16	2cbed6462fea2622871bb7e49b0df3d984239281
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	STK36 RELN FRMPD4 CFTR SSPOP PTPRQ PCDH15 USH2A UNC79 NRCAM PIEZO2 TENM4 HMCN1 XIRP2 HYDIN DNAH11	1.28e-13	184	296	16	2b19a8c5f823e00812908b23e66bb4e563278aff
ToppCell	facs-Thymus-Thymus_Epithelium-18m-Lymphocytic\|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation	STK36 RELN FRMPD4 CFTR SSPOP PTPRQ PCDH15 USH2A UNC79 NRCAM PIEZO2 TENM4 HMCN1 XIRP2 HYDIN DNAH11	1.28e-13	184	296	16	ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	PDGFRB SLCO3A1 BMP4 PXDNL FN1 NRCAM SPECC1L REV3L GTF3C1 MICALL2 VCAN SLIT3 PLXNA4 TNXB CDH11	6.46e-12	200	296	15	9b0916d8d07ac2bf1739f7be5296bf77ffee6094
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	PDGFRB SLCO3A1 ADARB1 BMP4 PXDNL FN1 NRCAM SPECC1L REV3L VCAN SLIT3 PLXNA4 TNXB CDH11	7.74e-11	199	296	14	a7dd94b172c973a131a6792f8ccd9bfe44d984ac
ToppCell	Control_saline-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|Control_saline / Treatment groups by lineage, cell group, cell type	PDGFRB BMP4 PXDNL PCDH15 CNTFR NAALAD2 FN1 NRCAM SPECC1L MICALL2 VCAN SLIT3 TNXB CDH11	8.27e-11	200	296	14	bd8cf33502adea320e91ca2af14e1911d88ad374
ToppCell	Control-Fibroblasts-Airway_smooth_muscle\|Control / group, cell type (main and fine annotations)	PDGFRB SPEG ITGA7 ADARB1 AEBP1 PXDNL MMP16 FN1 FAM13C NLGN1 VCAN SLIT3 CDH11	2.68e-10	180	296	13	d0de12749ef0f51f0931c6e7b9b99966bdbc3ec1
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FRMPD4 PDGFRB SLCO3A1 ADARB1 AEBP1 PXDNL PCDH15 NRCAM PIEZO2 VCAN SLIT3 PLXNA4 CDH11	5.57e-10	191	296	13	b13229bb7f3713a392271aaf5dbae3edd1b9fe5a
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FRMPD4 PDGFRB SLCO3A1 ADARB1 BMP4 AEBP1 PXDNL PCDH15 NRCAM PIEZO2 SLIT3 PLXNA4 CDH11	5.94e-10	192	296	13	6f4ef24dab544681304b7f8a9dc073e7edaa4cf5
ToppCell	IPF-Stromal-Myofibroblast\|Stromal / Disease state, Lineage and Cell class	TRPS1 CDH23 FRMD4B NEO1 CSGALNACT2 FN1 ANK3 PIEZO2 TENM4 HMCN1 VCAN ENTPD1 CDH11	8.15e-10	197	296	13	f304d42fc4936fe20996e07c8dccc698a6e5e5ef
ToppCell	Control_saline-Mesenchymal_fibroblastic\|Control_saline / Treatment groups by lineage, cell group, cell type	PDGFRB BMP4 PXDNL PCDH15 CNTFR NAALAD2 FN1 NRCAM SPECC1L VCAN SLIT3 TNXB CDH11	9.81e-10	200	296	13	64ae5cf6cb4fc94cf1052abd82648f6b8e6445fe
ToppCell	Control_saline-Mesenchymal_fibroblastic-Fibroblasts\|Control_saline / Treatment groups by lineage, cell group, cell type	PDGFRB BMP4 PXDNL PCDH15 CNTFR NAALAD2 FN1 NRCAM SPECC1L VCAN SLIT3 TNXB CDH11	9.81e-10	200	296	13	a1fc74c1b27e104895910bc7cdce7ba33d30df7e
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PDGFRB SLCO3A1 ADARB1 AEBP1 PXDNL PCDH15 CNTFR NRCAM PIEZO2 SLIT3 PLXNA4 CDH11	5.68e-09	189	296	12	e9d5e858e320c6e9913c1ea6a54967d21eda605f
ToppCell	LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PDGFRB ADARB1 BMP4 AEBP1 PXDNL PCDH15 ASTN2 NRCAM PIEZO2 SLIT3 PLXNA4 CDH11	5.68e-09	189	296	12	2a22b9fae70afb3dab8476f9c00e48a4df756410
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PDGFRB SLCO3A1 ADARB1 SORCS2 PCDH15 NRCAM REV3L PIEZO2 VCAN SLIT3 PLXNA4 CDH11	6.03e-09	190	296	12	45df8fee00f8949937863159d7aa042e72748d9b
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FRMPD4 PDGFRB ADARB1 BMP4 AEBP1 PXDNL PCDH15 NAALAD2 PIEZO2 SLIT3 PLXNA4 CDH11	6.03e-09	190	296	12	841cd55861b43578d704418b9bc0af2e8b88323a
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PDGFRB SLCO3A1 ADARB1 AEBP1 PXDNL PCDH15 FN1 NRCAM PIEZO2 SLIT3 PLXNA4 CDH11	6.78e-09	192	296	12	3d0cb19f037f604253d7d728689aeaa94251e92b
ToppCell	LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FRMPD4 PDGFRB ADARB1 PXDNL PCDH15 ASTN2 NAALAD2 NRCAM PIEZO2 SLIT3 PLXNA4 CDH11	7.19e-09	193	296	12	fb28717fadd06c3840636d25409ce80c9254bd34
ToppCell	PCW_05-06-Mesenchymal\|PCW_05-06 / Celltypes from embryonic and fetal-stage human lung	PDGFRB TRPS1 BMP4 CNTFR NAALAD2 FN1 FAM13C PIEZO2 TENM4 VCAN SLIT3 CDH11	8.54e-09	196	296	12	dca52c57ba35d9395cdbca8b881f12ece721b10f
ToppCell	Control-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ADARB1 PXDNL PCDH15 ASTN2 NAALAD2 NRCAM PIEZO2 SLIT3 ASPA PLXNA4 TNXB	3.66e-08	180	296	11	08ae0f5d95c45feba68ad99788f7af7ff4c979af
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FRMPD4 ADARB1 BMP4 AEBP1 PXDNL PCDH15 NRCAM PIEZO2 SLIT3 PLXNA4 CDH11	6.03e-08	189	296	11	a153b83314cf52808f685296cff8c95af3f4983d
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PDGFRB SLCO3A1 ADARB1 AEBP1 PXDNL PCDH15 NRCAM PIEZO2 SLIT3 PLXNA4 CDH11	7.08e-08	192	296	11	f4fc2b0121f879bab2bee99dfb5ff2c3ca1c0e1b
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FRMPD4 ADARB1 BMP4 AEBP1 PXDNL PCDH15 NRCAM PIEZO2 SLIT3 PLXNA4 CDH11	7.08e-08	192	296	11	dcd924d6eb67d33ee9f5d3e8ab6e1d4283d6b708
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FRMPD4 SLCO3A1 ADARB1 PXDNL PCDH15 NAALAD2 NRCAM PIEZO2 SLIT3 PLXNA4 CDH11	7.87e-08	194	296	11	60622bd2f75bfe4c37f721cb12f03dab33f2f58d
ToppCell	Adult-Mesenchymal-matrix_fibroblast_1_cell\|Adult / Lineage, Cell type, age group and donor	PDGFRB ADARB1 AEBP1 PCDH15 FN1 PIEZO2 HMCN1 SLIT3 ASPA TNXB CDH11	8.29e-08	195	296	11	61c9e09fc84d1012e472185d70ad0a06cee30d6e
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	PDGFRB ADARB1 AEBP1 PCDH15 FN1 PIEZO2 HMCN1 SLIT3 ASPA TNXB CDH11	8.29e-08	195	296	11	4243190ad291d56694e2155954dbaa879c9d3844
ToppCell	LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB\|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type	SLCO3A1 ADARB1 BMP4 BSN NRCAM REV3L GRM8 MICALL2 SLIT3 TNXB CDH11	9.20e-08	197	296	11	fdb92985f7df0c280b87d3e43c2394e70786a2c7
ToppCell	COVID-19-lung-Fibroblast\|lung / Disease (COVID-19 only), tissue and cell type	PDGFRB ADARB1 AEBP1 FN1 NRCAM PIEZO2 HMCN1 VCAN SLIT3 PLXNA4 CDH11	9.68e-08	198	296	11	df3de77216f5c5d6141ec44d01c56b942f611838
ToppCell	COVID-19-lung-Fibroblast\|COVID-19 / Disease (COVID-19 only), tissue and cell type	PDGFRB CDH23 ADARB1 AEBP1 FN1 NRCAM PIEZO2 HMCN1 VCAN SLIT3 CDH11	9.68e-08	198	296	11	3ec01a55ade5e1627258cc3cfebb2c3207a4cb43
ToppCell	Parenchymal-NucSeq\|Parenchymal / Cell types per location group and 10X technology with lineage, and cell group designations	ARHGAP32 ACACA MYO9A SLCO3A1 ATP11A SHROOM3 ANK3 GPR39 SMURF1 AMBRA1 ZSWIM6	9.68e-08	198	296	11	1996373bdccc55aac347d349bd22f6aad6d0c668
ToppCell	Control_saline-Mesenchymal_fibroblastic-Fibroblasts-Diff_MatrixFB\|Control_saline / Treatment groups by lineage, cell group, cell type	PDGFRB BMP4 PXDNL CNTFR NAALAD2 FN1 SPECC1L VCAN SLIT3 TNXB CDH11	1.02e-07	199	296	11	c2c42ecf20d1924edc2f899c01dfa5fcf3c210b9
ToppCell	Tracheal-NucSeq\|Tracheal / Cell types per location group and 10X technology with lineage, and cell group designations	ARHGAP32 ACACA VWA8 TRPS1 UBR5 HERC1 UTRN ANK3 AMBRA1 ZSWIM6 SOS1	1.02e-07	199	296	11	94b94b17ca18b8dc27b91da1f2ccf89e03cc7035
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	PDGFRB BMP4 PXDNL NAALAD2 FN1 NRCAM SPECC1L VCAN SLIT3 TNXB CDH11	1.02e-07	199	296	11	30d3e8c0681ec11f86dd38c5f48d21187a1b4f90
ToppCell	LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB\|LPS_IL1RA / Treatment groups by lineage, cell group, cell type	AHI1 PDGFRB SLCO3A1 PCDH15 REV3L MICALL2 VCAN SLIT3 PLXNA4 TNXB CDH11	1.02e-07	199	296	11	8b86c69aaf60feff53aa782559cfece7342a23de
ToppCell	Bronchial-NucSeq-Stromal-Fibroblastic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	PDGFRB ADARB1 AEBP1 FN1 PIEZO2 HMCN1 VCAN SLIT3 ASPA TNXB CDH11	1.07e-07	200	296	11	cae972324d1dfea6efeaf6013f265c7c6bb48db4
ToppCell	Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_alveolar\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	PDGFRB BMP4 AEBP1 STARD9 MMP16 NAALAD2 HMCN1 VCAN ASPA TNXB CDH11	1.07e-07	200	296	11	3dd022e974fec7013ba18f333da63f58fbf2dd7c
ToppCell	Parenchymal-NucSeq-Stromal-Fibroblastic\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	PDGFRB ADARB1 AEBP1 PCDH15 FN1 PIEZO2 HMCN1 VCAN SLIT3 TNXB CDH11	1.07e-07	200	296	11	311fab076f2ceb258e3970eb21e39344b894042a
ToppCell	facs-Diaphragm-Limb_Muscle-24m\|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	ADAM28 AEBP1 PCDH15 USH2A UNC79 NLGN1 CUBN PLXNA4 HYDIN DNAH11	2.08e-07	169	296	10	12bdc709bc000d7f9061ecd9fbd57233eaacb7e2
ToppCell	343B-Fibroblasts-Fibroblast-A_(Fibroblast_progenitors)-\|343B / Donor, Lineage, Cell class and subclass (all cells)	PDGFRB AEBP1 NAALAD2 FN1 NRCAM VCAN SLIT3 ASPA TNXB CDH11	3.03e-07	176	296	10	2e94bbe17c0bb65dc58b4ebc0cb829258bd7373b
ToppCell	343B-Fibroblasts-Fibroblast-A_(Fibroblast_progenitors)\|343B / Donor, Lineage, Cell class and subclass (all cells)	PDGFRB AEBP1 NAALAD2 FN1 NRCAM VCAN SLIT3 ASPA TNXB CDH11	3.03e-07	176	296	10	f33ab41d121b59d871ad7d48ca021524a027d2ef
ToppCell	Control-Stromal_mesenchymal-Matrix_Fibroblast\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	ADARB1 PXDNL PCDH15 ASTN2 NAALAD2 NRCAM PIEZO2 SLIT3 ASPA TNXB	3.72e-07	180	296	10	9b1de1b4711adbf9a423f4d2d08f3f4c78f1f8f4
ToppCell	5'-GW_trimst-1-SmallIntestine-Neuronal-neurons_B\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	APC2 SLCO3A1 ADGRG1 SHD MFNG TBX20 CUBN SLC6A3 PLXNA4 NDRG4	4.79e-07	185	296	10	d51342a3979bd728a80e04126059a3fd8a0dbe3b
ToppCell	5'-GW_trimst-1-SmallIntestine-Neuronal-neurons_B-Branch_B1_(eMN)\|GW_trimst-1 / Celltypes from developing, pediatric, Crohn's, & adult GI tract	APC2 SLCO3A1 ADGRG1 SHD MFNG TBX20 CUBN SLC6A3 PLXNA4 NDRG4	4.79e-07	185	296	10	ef996f4cdbc3971c6c0460d13df64b075ab22154
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	PDGFRB AEBP1 PCDH15 FN1 PIEZO2 HMCN1 SLIT3 ASPA TNXB CDH11	5.03e-07	186	296	10	5473283fb95cee556b1f6934cf72169b676b5bcc
ToppCell	LPS-IL1RA+antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MYO9A WWC2 ANOS1 PTPRQ ATP11A UTRN SHROOM3 GPR39 NLGN1 DENND3	5.03e-07	186	296	10	3aebe163799109ffc67e4e10ee47c2dd0886a92c
ToppCell	Adult-Mesenchymal-matrix_fibroblast_1_cell-D175\|Adult / Lineage, Cell type, age group and donor	CDH23 ADARB1 AEBP1 PCDH15 FN1 PIEZO2 HMCN1 SLIT3 TNXB CDH11	5.29e-07	187	296	10	e15d2967aac248da3517bc2c7d1beaa1d5a0aa7f
ToppCell	facs-Lung-18m-Mesenchymal-fibroblast-adventitial_fibroblast-adventitial_fibroblast_l17\|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype	PDGFRB MYOC SHC2 AEBP1 PCDH15 TBX20 IGSF3 C2orf88 VCAN TNXB	5.55e-07	188	296	10	bba6b273bd47dd0e27fde914e9e6fc9d76fd5176
ToppCell	Control-Fibroblasts\|Control / group, cell type (main and fine annotations)	ADARB1 AEBP1 PCDH15 FN1 PIEZO2 HMCN1 VCAN SLIT3 TNXB CDH11	6.12e-07	190	296	10	3a42a9b98d954685d38a741f44545898d0e3e9ce
ToppCell	Children_(3_yrs)-Epithelial\|Children_(3_yrs) / Lineage, Cell type, age group and donor	DDAH1 ACACA CFTR WWC2 SORCS2 ATP11A SHROOM3 ANK3 GPR39 LRRC36	6.42e-07	191	296	10	e432c6e1ae82dddf84314ce73d2b7a991630d905
ToppCell	LPS_only-Stromal_mesenchymal-Matrix_Fibroblast\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PDGFRB SLCO3A1 ADARB1 AEBP1 PCDH15 NRCAM PIEZO2 SLIT3 PLXNA4 CDH11	6.73e-07	192	296	10	ee085e04d5dcfb657522484ed20b8c1ddeccfe0c
ToppCell	LPS_only-Stromal_mesenchymal\|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PDGFRB SLCO3A1 ADARB1 AEBP1 PCDH15 NRCAM PIEZO2 SLIT3 PLXNA4 CDH11	6.73e-07	192	296	10	162d8b5858d150ecbbd1c9bf2b19c6c9cd50a158
ToppCell	LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB\|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PDGFRB SLCO3A1 ADARB1 PXDNL PCDH15 NRCAM PIEZO2 SLIT3 PLXNA4 CDH11	6.73e-07	192	296	10	deeecd26972241846b4cb998edf0c7a87ff0c4df
ToppCell	Adult-Mesenchymal-matrix_fibroblast_1_cell-D231\|Adult / Lineage, Cell type, age group and donor	PDGFRB ADARB1 AEBP1 PCDH15 FN1 PIEZO2 HMCN1 SLIT3 TNXB CDH11	7.06e-07	193	296	10	ef2f456c094e6e3c6ee81e0668c953cb8d0e1c0a
ToppCell	LPS-antiTNF-Stromal_mesenchymal\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	PDGFRB ADARB1 AEBP1 PXDNL PCDH15 FN1 PIEZO2 SLIT3 PLXNA4 CDH11	7.40e-07	194	296	10	6e13549f697f7478b34fe71f7dd9d63c5d3db22e
ToppCell	LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	FRMPD4 SLCO3A1 ADARB1 PXDNL PCDH15 NRCAM PIEZO2 SLIT3 PLXNA4 CDH11	7.40e-07	194	296	10	89b706af2b25991fc2707eb24f49ba6ff3ae01f7
ToppCell	TCGA-Stomach-Primary_Tumor-Stomach_Adenocarcinoma-Stomach_Adenocarcinoma_-_NOS-3\|TCGA-Stomach / Sample_Type by Project: Shred V9	PDGFRB ANOS1 CSGALNACT2 AEBP1 SORCS2 PIEZO2 HMCN1 VCAN ENTPD1 CDH11	7.40e-07	194	296	10	2260cd817a6661e5eb6645b0c6786e18fd58371e
ToppCell	COVID-19-Fibroblasts-Alveolar_FB\|COVID-19 / group, cell type (main and fine annotations)	ADARB1 PCDH15 FN1 NRCAM PIEZO2 HMCN1 SLIT3 PLXNA4 TNXB CDH11	7.76e-07	195	296	10	603050beeb33c331d4b2e3fa46cae3f3e0e4bdc7
ToppCell	PCW_10-12-Mesenchymal-Mesenchymal_fibroblastic-mes_immature3_(17)\|PCW_10-12 / Celltypes from embryonic and fetal-stage human lung	PDGFRB FRMD4B NAALAD2 FN1 NLGN1 PIEZO2 VCAN SLIT3 ASPA CDH11	7.76e-07	195	296	10	1cdf5f296029ae424d9dba42e86a6d111e4896e6
ToppCell	5'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.0\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	PDGFRB ADARB1 AEBP1 PCDH15 FN1 PIEZO2 HMCN1 SLIT3 TNXB CDH11	7.76e-07	195	296	10	df409f94f4e83be89f7a608058ee07ce3ce3a149
ToppCell	PCW_07-8.5-Mesenchymal\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	PDGFRB CNTFR NAALAD2 FN1 FAM13C PIEZO2 TENM4 VCAN SLIT3 CDH11	8.13e-07	196	296	10	8e10802f52e5e1853ea4ad34bf9a32a34e6112b5
ToppCell	Children_(3_yrs)-Mesenchymal\|Children_(3_yrs) / Lineage, Cell type, age group and donor	PDGFRB ADARB1 AEBP1 PCDH15 FN1 PIEZO2 HMCN1 SLIT3 TNXB CDH11	8.13e-07	196	296	10	bc94909f9b2dc08a59eef1914148b69720569c8f
ToppCell	10x_3'_v2v3-Non-neoplastic-Vascular-Mural_cell-Pericyte-G\|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group	PDGFRB TINAGL1 PXDNL A4GALT PEAR1 FN1 GRM8 PIEZO2 SLIT3 CDH11	8.13e-07	196	296	10	73f029d2b276776d6c24356b14c6592c9cb74bd5
ToppCell	3'-Parenchyma_lung-Mesenchymal-Fibroblastic-fibroblastic_type_2-Alveolar_fibroblasts-Alveolar_fibroblasts_L.2.1.1.0\|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	ADARB1 AEBP1 PCDH15 FN1 PIEZO2 HMCN1 SLIT3 ASPA TNXB CDH11	8.51e-07	197	296	10	13896ec65ccda0b928c91d41112dc01b480036b7
ToppCell	PCW_13-14-Mesenchymal-Mesenchymal_fibroblastic-mes_immature3_(17)\|PCW_13-14 / Celltypes from embryonic and fetal-stage human lung	PDGFRB FRMD4B NAALAD2 FN1 NLGN1 PIEZO2 VCAN SLIT3 ASPA CDH11	8.51e-07	197	296	10	31a1852911bda38543916585fda34255fd62a134
ToppCell	COVID-19-Fibroblasts-Intermediate_pathological_FB\|COVID-19 / group, cell type (main and fine annotations)	PDGFRB AEBP1 FN1 NRCAM PIEZO2 TENM4 HMCN1 VCAN SLIT3 CDH11	8.51e-07	197	296	10	f1c8936986123a3151140c374fcd62d6705c530b
ToppCell	Primary_Visual_cortex_(V1C)-Neuronal\|Primary_Visual_cortex_(V1C) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types	ARHGAP32 AHI1 FRMPD4 SLC12A5 UNC79 NRCAM KSR2 TENM4 SLC4A10 NDRG4	8.91e-07	198	296	10	8ab40fae14fe02e39bc8c8da187a5cd60c787643
ToppCell	10x3'2.3-week_17-19-Mesenchymal_fibro-stroma-arteriolar_fibroblast\|week_17-19 / cell types per 3 fetal stages;per 3',per 5'	PDGFRB MYOC ANOS1 CNTFR FN1 FAM13C SCG5 PIEZO2 ASPA TNXB	9.33e-07	199	296	10	95d95e9b7bd3933188998ae94986213eb0f1e5ea
ToppCell	LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB\|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type	PDGFRB SLCO3A1 BMP4 PXDNL SPECC1L REV3L VCAN SLIT3 TNXB CDH11	9.33e-07	199	296	10	e1849505b92820a219c5a2c35492bdd55579fb48
ToppCell	Mesenchymal\|World / Lineage, Cell type, age group and donor	PDGFRB ADARB1 AEBP1 FN1 PIEZO2 HMCN1 SLIT3 ASPA TNXB CDH11	9.33e-07	199	296	10	4bac110c2b3609f6ee5d0e3275da0824a6240270
ToppCell	Bronchial-NucSeq-Stromal\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	PDGFRB ADARB1 AEBP1 FN1 PIEZO2 HMCN1 VCAN SLIT3 TNXB CDH11	9.76e-07	200	296	10	389cc775c8419d90fb77cd794376d2160a7bf44e
ToppCell	Brain_organoid-organoid_Tanaka_cellReport-1m-Mesenchymal-Mesoderm\|1m / Sample Type, Dataset, Time_group, and Cell type.	NOL6 ATG2A PAK6 PTH2R HERC1 PLEKHA4 PMEL TEX14 MICALL2 ENTPD1	9.76e-07	200	296	10	c0ad32e9dd7f481c2665587fd8bd9fffc2e725f9
ToppCell	Parenchymal-NucSeq-Stromal\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	PDGFRB ADARB1 AEBP1 FN1 PIEZO2 HMCN1 VCAN SLIT3 TNXB CDH11	9.76e-07	200	296	10	cf433f9b43d7db07acaf70e060f8f77c974e72f3
ToppCell	LPS_only-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB\|LPS_only / Treatment groups by lineage, cell group, cell type	PDGFRB BMP4 PXDNL REV3L MICALL2 VCAN SLIT3 PLXNA4 TNXB CDH11	9.76e-07	200	296	10	a7ef7022b8efcaedb7319b0b43d8c4e99d788fe2
ToppCell	Bronchial-NucSeq-Stromal-Fibroblastic-Fibro_alveolar\|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations	PDGFRB ADARB1 PCDH15 FN1 PIEZO2 HMCN1 SLIT3 ASPA TNXB CDH11	9.76e-07	200	296	10	e8462395fee0a532d1e7ec7f1795f28c42af6541
ToppCell	343B-Epithelial_cells-Epithelial-H_(AT1)-\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	RELN ADAM28 TINAGL1 FAT2 A4GALT HPDL S1PR5 HMCN1 ASPA	1.36e-06	161	296	9	da9eecf919866a9c579d7a707a996cf335213134
ToppCell	343B-Epithelial_cells-Epithelial-H_(AT1)\|Epithelial_cells / Donor, Lineage, Cell class and subclass (all cells)	RELN ADAM28 TINAGL1 FAT2 A4GALT HPDL S1PR5 HMCN1 ASPA	1.36e-06	161	296	9	d431625c32f59a6b552191f3adc5198bd16ad5cf
ToppCell	10x5'-blood-Lymphocytic_T_CD4-T_CD4/CD8\|blood / Manually curated celltypes from each tissue	SPEG PHC3 AP3M2 N4BP2L2 UTRN ANK3 SFXN1 DDHD1 PCSK7	1.43e-06	162	296	9	b4535bcb3f469bc139e73f1122f4070013e5a1de
ToppCell	5'-Airway_Nasal-Mesenchymal-Fibroblastic-fibroblastic_type_1\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CEACAM5 PDGFRB AEBP1 SORCS2 FN1 SCG5 CUBN GRM8 SLIT3	1.85e-06	167	296	9	31cf8bf2eb523f6e7e319620648ff37fc09e2601
ToppCell	5'-Airway_Nasal-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts-\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CEACAM5 PDGFRB AEBP1 SORCS2 FN1 SCG5 CUBN GRM8 SLIT3	1.85e-06	167	296	9	805129f887078340b260aa136b0ba19f2bd6ea03
ToppCell	5'-Airway_Nasal-Mesenchymal-Fibroblastic-fibroblastic_type_1-Adventitial_fibroblasts\|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5	CEACAM5 PDGFRB AEBP1 SORCS2 FN1 SCG5 CUBN GRM8 SLIT3	1.85e-06	167	296	9	3acb18428d1d33ad430c2fd031b1a91baee3c01d
ToppCell	Control-Epithelial_alveolar-AT_1-Differentiating_AT1\|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	CEACAM5 MYO9A ANOS1 PTPRQ UTRN SHROOM3 GPR39 NLGN1 DENND3	2.98e-06	177	296	9	9af14a056eb6d88c6f11b09f6d4c0d3448d647d5
ToppCell	COPD-Epithelial-Basal\|Epithelial / Disease state, Lineage and Cell class	FRMPD4 BCL11A FRMD4B ADAM28 TINAGL1 ANOS1 FAT2 ZSWIM6 ARG2	3.12e-06	178	296	9	441d1dba720141891b11f404744c59834d80e6c5
ToppCell	TCGA-Colorectal-Primary_Tumor-Colorectal_Adenocarcinoma-Rectal_Adenocarcinoma-7\|TCGA-Colorectal / Sample_Type by Project: Shred V9	PDGFRB ANOS1 AEBP1 FN1 PTF1A PIEZO2 HMCN1 VCAN CDH11	3.12e-06	178	296	9	edc76b8f15056ec1c9a1c61a048b6331a92592d6
ToppCell	droplet-Heart-4Chambers-21m-Mesenchymal-nan\|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation	STK36 PDGFRB ITGA7 MTHFD2L UNC79 PCDHGA4 HPDL ANGPTL6 KCTD14	3.27e-06	179	296	9	b44e2d53b82c3c141bfc6539054b19708200a0d9
ToppCell	COVID-19-kidney-REN+Pericyte\|kidney / Disease (COVID-19 only), tissue and cell type	PDGFRB SLCO3A1 TINAGL1 STARD9 MMP16 PEAR1 FN1 PIEZO2 SLIT3	3.27e-06	179	296	9	342c1cc4444f51b8dcb30d3adc98285a25669c6e
ToppCell	facs-Kidney-nan-24m-Mesenchymal\|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	PDGFRB AEBP1 UNC79 NPHS1 FN1 SLC4A1 SLC7A4 TNXB CDH11	3.42e-06	180	296	9	f9f8245cbcdea18c15e2976c85b72c6807309787
ToppCell	LPS-antiTNF-Epithelial_alveolar-AT_1-Differentiating_AT1\|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2	MYO9A WWC2 ANOS1 PTPRQ SORCS2 UTRN SHROOM3 NLGN1 DENND3	3.58e-06	181	296	9	b45b11428d13950369347e051d4d517efb2bd4fd
ToppCell	Children_(3_yrs)-Mesenchymal-matrix_fibroblast_1_cell-D046\|Children_(3_yrs) / Lineage, Cell type, age group and donor	ADARB1 PCDH15 NAALAD2 FN1 PIEZO2 HMCN1 SLIT3 ASPA CDH11	3.58e-06	181	296	9	9ede19228ba5c0668a9c06c915510b95585216ef
ToppCell	NS-moderate-d_16-33-Lymphoid-NK\|d_16-33 / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined)	PDGFRB AEBP1 FN1 NRCAM SCG5 NLGN1 PMEL ASPA DCHS1	3.74e-06	182	296	9	fb503f8ecd013f1f2161a5841572b57cfcddb6fa
ToppCell	TCGA-Lung-Primary_Tumor-Lung_Carcinoma-Lung_Squamous_Cell_Carcinoma-3\|TCGA-Lung / Sample_Type by Project: Shred V9	LSG1 BCL11A FAT2 IGSF3 NRCAM DSG3 S1PR5 TENM4 NDRG4	4.09e-06	184	296	9	ea4ccebe2d54279fcc517e4f0bfa652b91a808bb
ToppCell	nucseq-Epithelial-Epithelial_Alveolar-AT1-AT1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	WWC2 ANOS1 PTPRQ ATP11A UTRN SHROOM3 GPR39 PTPN21 DENND3	4.09e-06	184	296	9	57c792e6e2fedba25d3350ffe649fd74750b579d
ToppCell	droplet-Bladder-BLADDER-1m-Epithelial-luminal_bladder_epithelial_cell_(umbrella_cell)\|Bladder / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation	SREBF1 ADAM28 FAT2 CNGA3 HOXB13 KRTCAP3 SYNGR1 REEP4 EPHA1	4.09e-06	184	296	9	382b1e90b3f437af596750669c0465a169d97095
ToppCell	BAL-Control-Myeloid-cDC-cDC-cDC_2\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)	BCL11A ADAM8 MS4A4E ADAM28 IGSF3 AMPD3 GPR39 TLR10 ENTPD1	4.09e-06	184	296	9	0a26bcc6610f756939e32a4d6dfeebcbf3a1db86
ToppCell	nucseq-Epithelial-Epithelial_Alveolar-AT1\|nucseq / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2	WWC2 ANOS1 PTPRQ ATP11A UTRN SHROOM3 GPR39 PTPN21 DENND3	4.09e-06	184	296	9	d7bd0f0c607bade67c99e9fb3578a570298bf926
ToppCell	droplet-Liver-LIVER_HEP-30m-Mesenchymal\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RELN PDGFRB ASTN2 TBX20 NAALAD2 ANK3 PIEZO2 TNXB NDRG4	4.27e-06	185	296	9	f814ec9d4ade717a0109398e9768d0d66f09317b
ToppCell	droplet-Liver-LIVER_HEP-30m-Mesenchymal-hepatic_stellate_cell\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RELN PDGFRB ASTN2 TBX20 NAALAD2 ANK3 PIEZO2 TNXB NDRG4	4.27e-06	185	296	9	40e958511790e84321da5ccf735f9974c06a0263
ToppCell	PCW_07-8.5-Mesenchymal-Mesenchymal_fibroblastic-mes_immature_COL13A1^pos_fibro2_(5)\|PCW_07-8.5 / Celltypes from embryonic and fetal-stage human lung	TRPS1 CDH23 BCL11A ADARB1 BMP4 FN1 TENM4 VCAN CDH11	4.27e-06	185	296	9	1ac6a32cc56d5d819649bdd99518e2ead0eead4c
ToppCell	BAL-Control-Myeloid-cDC-cDC-cDC_2\|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)	BCL11A ADAM8 MS4A4E ADAM28 IGSF3 AMPD3 GPR39 TLR10 ENTPD1	4.27e-06	185	296	9	fec16a5e527fdef32d25957451b6e8ee9796cafd
ToppCell	droplet-Liver-LIVER_HEP-30m-Mesenchymal-hepatic_stellate_cell\|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation	RELN PDGFRB ASTN2 TBX20 NAALAD2 ANK3 PIEZO2 TNXB NDRG4	4.27e-06	185	296	9	5f2eeba80aff145e85cfd81e2890a155406badb9
ToppCell	systemic_lupus_erythematosus-flare-Lymphocytic_NK-NK_dim-male\|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex	PDGFRB ADGRG1 ADAM8 UTRN PLAAT4 TBX21 S1PR5 SYNGR1 PCSK7	4.67e-06	187	296	9	0bca79cea4886b66350c56c61859bd71e1e7a85c
Drug	Metolazone [17560-51-9]; Down 200; 11uM; PC3; HT_HG-U133A	TPRA1 AHI1 SPEG CUL7 CDC73 IGSF3 DNAH3 RNF31 ARFGEF1 GATC PIGZ SYNGR1 PCSK7 SOS1	3.34e-07	198	295	14	6292_DN
Drug	AC1L1AUZ	CEACAM5 CFTR ITGA7 ADARB1 ANOS1 SARS2 GLB1 DLG3 UTRN AATF EMD HTT	1.03e-06	157	295	12	CID000001160
Drug	SC 19220; Down 200; 10uM; PC3; HT_HG-U133A	VWA8 VPS13C BCL11A NUP210 RNF31 DENND3 RABL6 MICALL2 ZNF75D EMD NDRG4 EDRF1 JHY	1.44e-06	192	295	13	7065_DN
Drug	felodipine; Down 200; 10uM; MCF7; HT_HG-U133A_EA	AHI1 ACACA RPS6KA1 ZNF318 ATG2A SLC12A5 BMP4 WWC2 DNAH3 NRCAM SMURF1 PIGZ SLC9A2	1.81e-06	196	295	13	848_DN
Drug	Tubocurarine chloride pentahydrate (+) [6989-98-6]; Down 200; 5.2uM; MCF7; HT_HG-U133A	INPP1 DYRK4 PHC3 MFNG PIK3C2B A4GALT MERTK MMP16 PLK3 PLXNA3 AMPD3 SMURF1 CRY2	1.92e-06	197	295	13	2887_DN
Drug	Probenecid [57-66-9]; Up 200; 14uM; PC3; HT_HG-U133A	CYP2C9 TSPOAP1 PAK6 FRMD4B SHC2 ATP11A MERTK CRAT CRY2 ZNF750 SYNGR1 KCTD14 LRRC8B	2.03e-06	198	295	13	4185_UP
Drug	Pluronic	RELN CEACAM5 ITGA7 GLB1 UTRN DSG3 VCAN EMD HTT	2.57e-06	90	295	9	CID000024751
Drug	sitaxsentan	CYP2C19 CYP2C8 CYP2C9 FN1	5.45e-06	10	295	4	ctd:C106276
Drug	nirvanol	CYP2C19 CYP2C8 CYP2C9 UBR5 EPHA1	6.06e-06	21	295	5	CID000091480
Drug	Tolnaftate [2398-96-1]; Down 200; 13uM; MCF7; HT_HG-U133A	INPP1 DYRK4 ASTN2 UTRN PLXNA3 DNAH3 RNF31 PMEL CRY2 ENTPD1 SYNGR1 ZNF75D	9.73e-06	195	295	12	1501_DN
Drug	Fluticasone propionate [80474-14-2]; Down 200; 8uM; PC3; HT_HG-U133A	ARHGAP32 BCL11A MFNG RAB3GAP2 NUP210 MMP16 NAALAD2 PTPN21 GRM8 RABL6 VCAN NDRG4	9.73e-06	195	295	12	4011_DN
Drug	fluphenazine dihydrochloride; Down 200; 10uM; MCF7; HT_HG-U133A	ZNF318 SALL2 NUP210 DLG3 MYO19 PTPN21 CRAT CRY2 RIOX2 RABL6 EPHA1 CAPN15	1.02e-05	196	295	12	1662_DN
Drug	Rapamycin; Down 200; 0.1uM; HL60; HT_HG-U133A	ARHGAP32 AHI1 MYO9B ADAM8 PIK3C2B ATP11A FN1 RNF31 AMBRA1 DHX57 PCSK7 EDRF1	1.08e-05	197	295	12	1183_DN
Drug	Ethoxyquin [91-53-2]; Down 200; 18.4uM; PC3; HT_HG-U133A	ADARB1 PHC3 C1orf105 ATP11A PLXNA3 AMPD3 PLAAT4 PTPN21 DENND3 RABL6 ARSD LRRC8B	1.14e-05	198	295	12	3764_DN
Drug	Doxycycline hydrochloride [10592-13-9]; Up 200; 8.4uM; HL60; HT_HG-U133A	PIK3IP1 MMP16 NAALAD2 ANK3 FAM13C SMURF1 NLGN1 GRM8 SLC6A9 NCOR2 SLC9A2 KIF1C	1.14e-05	198	295	12	2737_UP
Drug	Nomegestrol acetate [58652-20-3]; Down 200; 10.8uM; PC3; HT_HG-U133A	TPRA1 PHC3 MFNG SALL2 NUP210 ASTN2 UTRN AMBRA1 PTPN21 VCAN PCSK7 NDRG4	1.14e-05	198	295	12	6362_DN
Drug	Harpagoside [19210-12-9]; Down 200; 8uM; PC3; HT_HG-U133A	AHI1 NCBP1 ITGA7 NUP210 MMP16 RPGRIP1L SMURF1 PTPN21 DENND3 ARG2 MICALL2 EDRF1	1.19e-05	199	295	12	6636_DN
Drug	dobutamine	CEACAM5 PDGFRB ITGA7 SARS2 GLB1 UTRN DSG3 VCAN EMD HTT	1.49e-05	140	295	10	CID000036811
Drug	7-hydroxyquinoline	CYP2C19 CYP2C8 CYP2C9 DSG3	1.80e-05	13	295	4	CID000011378
Drug	bufuralol	CYP2C19 CYP2C8 CYP2C9	2.11e-05	5	295	3	ctd:C010831
Drug	4,4'-cyclohexylidenebisphenol	CYP2C19 CYP2C8 CYP2C9	4.18e-05	6	295	3	ctd:C570106
Drug	4',5-dihydroxydiclofenac	CYP2C19 CYP2C8 CYP2C9	4.18e-05	6	295	3	CID003052567
Drug	AC1O5Z5L	CYP2C19 CYP2C8 CYP2C9	4.18e-05	6	295	3	CID006443527
Drug	3'-hydroxydiclofenac	CYP2C19 CYP2C8 CYP2C9	4.18e-05	6	295	3	CID000112230
Drug	4,4'-(hexafluoroisopropylidene)diphenol	CYP2C19 CYP2C8 CYP2C9 SREBF1	4.44e-05	16	295	4	ctd:C571725
Drug	Theobromine [83-67-0]; Down 200; 22.2uM; PC3; HT_HG-U133A	MR1 PLEKHB1 PIK3IP1 CEP350 TINAGL1 C1orf105 MMP16 PLK3 RPGRIP1L RNF31 EPHA1	4.63e-05	193	295	11	6613_DN
Drug	Acyclovir [59277-89-3]; Down 200; 17.8uM; HL60; HG-U133A	ZNF318 BCL11A ATG2A PIK3C2B AP3M2 AEN PMEL ARG2 MICALL2 PCSK7 HTT	5.32e-05	196	295	11	2044_DN
Drug	Diflorasone Diacetate [33564-31-7]; Down 200; 8uM; MCF7; HT_HG-U133A	INPP1 DYRK4 PLEKHB1 STRN3 RPGRIP1L FN1 MYO19 AMBRA1 PTPN21 PIGZ EDRF1	5.32e-05	196	295	11	2798_DN
Drug	Napelline [5008-52-6]; Up 200; 11.2uM; MCF7; HT_HG-U133A	PIK3IP1 SHC2 AEBP1 ATP11A RPGRIP1L DICER1 DENND3 VCAN ENTPD1 DCHS1 LRRC8B	5.32e-05	196	295	11	6824_UP
Drug	Naringenine [480-41-1]; Up 200; 14.6uM; PC3; HT_HG-U133A	ITGA7 ADAM28 UTRN FN1 PMEL TEX14 CRY2 ENTPD1 SYNGR1 EDRF1 JHY	5.32e-05	196	295	11	4597_UP
Drug	Bromopride [4093-35-0]; Up 200; 11.6uM; MCF7; HT_HG-U133A	SLCO3A1 FRMD4B TINAGL1 RAB3GAP2 AMPD1 AMPD3 PMEL GRM8 DCHS1 CDH11 KIF1C	5.32e-05	196	295	11	4741_UP
Drug	rosiglitazone; Up 200; 10uM; MCF7; HT_HG-U133A	ACACA MYO9B PHC3 MMP16 AMPD3 FN1 SMURF1 COLGALT1 ZNF75D EDRF1 CAPN15	5.32e-05	196	295	11	1658_UP
Drug	sulindac sulfide; Down 200; 50uM; MCF7; HG-U133A	MYO9B MYOC RPS6KA1 SREBF1 SAG DLG3 UTRN FN1 PMEL ENTPD1 SLIT3	5.57e-05	197	295	11	308_DN
Drug	Propafenone hydrochloride [34183-22-7]; Down 200; 10.6uM; MCF7; HT_HG-U133A	VWA8 MYO9B RPS6KA1 PLEKHB1 SLC12A5 ASTN2 RPGRIP1L RNF31 SMURF1 PIGZ PCSK7	5.57e-05	197	295	11	5437_DN
Drug	Bendroflumethiazide [73-48-3]; Down 200; 9.4uM; MCF7; HT_HG-U133A	MYO9B SLCO3A1 BMP4 MFNG SAG UTRN CNTFR NLGN1 PTPN21 ARSD MAPKBP1	5.57e-05	197	295	11	3934_DN
Drug	Dimethisoquin hydrochloride [2773-92-4]; Down 200; 13uM; PC3; HT_HG-U133A	TINAGL1 DLG3 PLXNA3 AEN DNAH3 AMBRA1 PTPN21 SLC9A2 TENM4 VCAN CAPN15	5.57e-05	197	295	11	4207_DN
Drug	Vitamin K2 [11032-49-8]; Down 200; 9uM; PC3; HT_HG-U133A	CUL7 ITGA7 PLEKHB1 TINAGL1 UTRN AMPD3 MYO19 PTPN21 TENM4 ARSD EDRF1	5.57e-05	197	295	11	3798_DN
Drug	Bromopride [4093-35-0]; Up 200; 11.6uM; MCF7; HT_HG-U133A	PDGFRB MYO9B SPEG ITGA7 ADAM28 SAG AMPD1 FN1 TBX21 MAPKBP1 CDH11	5.57e-05	197	295	11	3617_UP
Drug	LY 294002; Down 200; 0.1uM; MCF7; HT_HG-U133A	ARHGAP32 TPRA1 SLCO3A1 BCR AEN GRM8 CRAT SLC9A2 PCSK7 MAPKBP1 SOS1	5.57e-05	197	295	11	6935_DN
Drug	Lysergol [602-85-7]; Down 200; 15.8uM; PC3; HT_HG-U133A	AHI1 CEACAM5 PHC3 N4BP2L2 ASTN2 MMP16 PLK3 DENND3 NCOR2 ENTPD1 SYNGR1	5.57e-05	197	295	11	6621_DN
Drug	LY 294002; Down 200; 10uM; HL60; HT_HG-U133A	TPRA1 NCBP1 FN1 RNF31 IRGQ SFXN1 VCAN LRRC8B REEP4 EDRF1 CAPN15	5.57e-05	197	295	11	1180_DN
Drug	Captopril [62571-86-2]; Up 200; 17.2uM; PC3; HG-U133A	CYP2C9 VWA8 MYO9B DLG3 DHX29 UTRN AEN SMURF1 IRGQ GRM6 MICALL2	5.83e-05	198	295	11	1907_UP
Drug	Dienestrol [84-17-3]; Down 200; 15uM; PC3; HT_HG-U133A	BCL11A BCR NUP210 PLAAT4 AMBRA1 CRY2 RABL6 SYNGR1 EDRF1 CAPN15 SOS1	5.83e-05	198	295	11	5727_DN
Drug	Azathioprine [446-86-6]; Up 200; 14.4uM; PC3; HT_HG-U133A	TSPOAP1 ADGRG1 ADARB1 CEP350 MERTK PLXNA3 RPGRIP1L FN1 PLAAT4 CRY2 KCTD14	5.83e-05	198	295	11	4667_UP
Drug	Nalidixic acid sodium salt hydrate; Down 200; 14.6uM; PC3; HT_HG-U133A	TPRA1 BCR PLEKHB1 MFNG C1orf105 ASTN2 DENND3 ENTPD1 KCTD14 PCSK7 EPHA1	6.10e-05	199	295	11	3668_DN
Drug	Benzocaine [94-09-7]; Up 200; 24.2uM; MCF7; HT_HG-U133A	FRMD4B SLC12A5 WWC2 SAG MERTK GRM8 SFXN1 NCOR2 LRRC8B EMD CAPN15	6.10e-05	199	295	11	2822_UP
Drug	Prednicarbate [73771-04-7]; Up 200; 8.2uM; MCF7; HT_HG-U133A	SPEG BCL11A SHC2 NUP210 MERTK NAALAD2 PLAAT4 CUBN VCAN EDRF1 JHY	6.10e-05	199	295	11	5544_UP
Drug	Guanabenz acetate [23256-50-0]; Down 200; 13.8uM; HL60; HG-U133A	PIK3C2B NUP210 ATP11A FN1 PMEL RNF123 METTL13 MICALL2 PCSK7 HTT SOS1	6.10e-05	199	295	11	2045_DN
Drug	Vitexin [3681-93-4]; Up 200; 9.2uM; PC3; HT_HG-U133A	AHI1 MR1 ADGRG1 NCBP1 PHC3 UTRN SCG5 SLC4A1 CRY2 VCAN ENTPD1	6.39e-05	200	295	11	4588_UP
Drug	Lysergol [602-85-7]; Up 200; 15.8uM; MCF7; HT_HG-U133A	AHI1 ADGRG1 ITGA7 PIK3IP1 BMP4 FN1 SMURF1 TENM4 ENTPD1 ACSL5 KIF1C	6.39e-05	200	295	11	4966_UP
Drug	Phentolamine hydrochloride [73-05-2]; Down 200; 12.6uM; MCF7; HT_HG-U133A	ADARB1 PIK3IP1 PHC3 C1orf105 MMP16 AMPD1 AMPD3 NCOR2 ENTPD1 MAPKBP1 JHY	6.39e-05	200	295	11	2323_DN
Drug	16-O-demethylaconitine	CYP2C19 CYP2C8 CYP2C9	7.25e-05	7	295	3	ctd:C486136
Drug	KW-2083	CEACAM5 GLB1 PCSK7	7.25e-05	7	295	3	CID000051036
Drug	5-fluorotryptamine	CYP2C19 CYP2C8 CYP2C9	7.25e-05	7	295	3	ctd:C034536
Drug	6-Fluoro-6-desoxyoxymorphone	CYP2C19 CYP2C8 CYP2C9	7.25e-05	7	295	3	CID005486899
Drug	perillyl alcohol	CYP2C19 CYP2C8 CYP2C9 PDGFRB SREBF1 PLEKHB1	8.47e-05	56	295	6	CID000010819
Drug	13-hydroxyeicosatetraenoic acid	CYP2C19 CYP2C8 CYP2C9	1.15e-04	8	295	3	CID006439499
Drug	11-HODE	CYP2C19 CYP2C8 CYP2C9	1.15e-04	8	295	3	CID006438497
Drug	5-bromotryptamine	CYP2C19 CYP2C8 CYP2C9	1.15e-04	8	295	3	ctd:C040997
Drug	1-(3-(4-phenoxyphenoxy)-2-oxopropyl)indole-5-carboxylic acid	CYP2C19 CYP2C8 CYP2C9	1.15e-04	8	295	3	ctd:C585955
Drug	fullerene C60	ACACA PDGFRB TSPOAP1 MYO9B ENTR1 APC2 SREBF1 POPDC2 ITGA7 ADAM8 ADARB1 IL22RA1 FRMD4B DDX1 PIK3IP1 CCM2 AEBP1 RAB3GAP2 PTPRQ XRN1 TIGD3 BSN IQGAP3 PLK3 VARS1 IGSF3 ESPN SHROOM3 ZNF775 CRAT DENND3 SLC4A1 ARG2 CRY2 TENM4 GTF3C1 LRRC8B	1.24e-04	1498	295	37	ctd:C069837
Drug	Papaverine hydrochloride [61-25-6]; Up 200; 10.6uM; HL60; HG-U133A	ARHGAP32 MYO9B ADARB1 SAG CNTFR RFNG ENTPD1 PCSK7 EMD REEP4	1.38e-04	182	295	10	1755_UP
Drug	thiotepa	STK36 CYP2C19 CYP2C8 CYP2C9 ITFG1	1.42e-04	39	295	5	CID000005453
Drug	Phenoxybenzamine hydrochloride [63-92-3]; Down 200; 11.8uM; MCF7; HT_HG-U133A	DDAH1 TRPS1 PTPRA MMP16 UTRN IGSF3 NRCAM NDST2 SLC9A2 ENTPD1	1.44e-04	183	295	10	5613_DN
Drug	Aspartylglutamate	PDGFRB SARS2 NAALAD2 GRM6 GRM8	1.60e-04	40	295	5	CID000151403
Drug	Spiperone [749-02-0]; Down 200; 10.2uM; PC3; HT_HG-U133A	MYO9B ZNF318 PAK6 PLEKHB1 SALL2 NUP210 HOXB13 DICER1 MICALL2 EPHA1	1.65e-04	186	295	10	5777_DN
Drug	dibenzylfluorescein	CYP2C19 CYP2C9	1.67e-04	2	295	2	ctd:C558664
Drug	eriochrome cyanin	CFTR BCR	1.67e-04	2	295	2	CID000075762
Drug	spiromesifen	ACACA BSN	1.67e-04	2	295	2	CID009907412
Drug	AC1NSSYM	SLC4A1 PCSK7	1.67e-04	2	295	2	CID005315347
Drug	AC1Q4Q30	STK36 ACACA GBA2	1.71e-04	9	295	3	CID000185818
Drug	Tryptamines	CYP2C19 CYP2C8 CYP2C9	1.71e-04	9	295	3	ctd:D014363
Drug	N-hydroxyglycine	AMPD1 AMPD3 XPNPEP1	1.71e-04	9	295	3	CID000019070
Drug	5-chlorotryptamine	CYP2C19 CYP2C8 CYP2C9	1.71e-04	9	295	3	ctd:C529169
Drug	3-(2-(4-(3-chloro-2-methylphenyl)1-piperazinyl)ethyl)5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazol dihydrochloride 3.5 hydrate	CYP2C19 CYP2C8 CYP2C9	1.71e-04	9	295	3	ctd:C109602
Drug	5-(N-(4-((4-ethylbenzyl)thio)phenyl)sulfamoyl)-2-methylbenzoic acid	CYP2C19 CYP2C8 CYP2C9	1.71e-04	9	295	3	ctd:C000588958
Drug	Flavonoids	DDAH1 ACACA SPEG CDH23 SLCO3A1 ITGA7 BCR BMP4 SAG UBR5 GPR149 PTPRQ CNGA4 ESPN AMPD1 AMPD3 NRCAM NLGN1 PTPN21 SLC6A9 SLC9A2 ENTPD1 SYNGR1 ASPA PRKAG1 PCSK7 AATF HTT SEZ6 KIF1C	1.83e-04	1136	295	30	ctd:D005419
Drug	17-AAG; Up 200; 1uM; PC3; HT_HG-U133A	VWA8 PIK3IP1 PHC3 ASTN2 MMP16 FN1 BAG3 CRY2 SYNGR1 EDRF1	1.88e-04	189	295	10	1225_UP
Drug	Naltrexone hydrochloride dihydrate [16676-29-2]; Down 200; 9.6uM; HL60; HG-U133A	CEACAM5 MYO9B ZNF318 BCR AMBRA1 IRGQ GRM6 DICER1 SYNGR1 CAPN15	2.22e-04	193	295	10	1363_DN
Drug	Cefazolin sodium salt [27164-46-1]; Up 200; 8.4uM; PC3; HT_HG-U133A	ARHGAP32 CFTR MR1 FAM13C NLGN1 GRM8 VCAN KCTD14 ZNF75D ACSL5	2.22e-04	193	295	10	7385_UP
Drug	Urapidil hydrochloride [64887-14-5]; Up 200; 9.4uM; PC3; HT_HG-U133A	ADGRG1 BCR ADARB1 SHC2 ATP11A UTRN FN1 GRM8 VCAN EPHA1	2.32e-04	194	295	10	6696_UP
Drug	haloperidol; Down 200; 10uM; HL60; HT_HG-U133A	ARHGAP32 MYO9B BCL11A ITGA7 WWC2 AEN DNAH3 DDX60 MICALL2 MAPKBP1	2.32e-04	194	295	10	1185_DN
Drug	Acetylsalicylsalicylic acid [530-75-6]; Down 200; 13.4uM; HL60; HG-U133A	CEACAM5 SREBF1 BCL11A CUL7 ADARB1 PIK3IP1 NUP210 UTRN FN1 AMBRA1	2.32e-04	194	295	10	1377_DN
Drug	0317956-0000 [391210-11-0]; Up 200; 10uM; MCF7; HT_HG-U133A	MR1 CUL7 PIK3IP1 PTPRA ATP11A MMP16 GPR39 TEX14 CRY2 NCOR2	2.32e-04	194	295	10	3855_UP
Drug	norketobemidone	CYP2C19 CYP2C8 CYP2C9	2.42e-04	10	295	3	CID000161154
Drug	5666823; Down 200; 100uM; MCF7; HG-U133A	MYO9B QRICH1 PIK3C2B NUP210 C1orf105 AEN AMPD3 FN1 REV3L RFNG	2.42e-04	195	295	10	609_DN
Drug	Butoconazole nitrate [32872-77-1]; Down 200; 8.4uM; MCF7; HT_HG-U133A	ADGRG1 PLEKHB1 BMP4 MFNG ATP11A DNAH3 PTPN21 PIGZ EPHA1 CAPN15	2.42e-04	195	295	10	5388_DN
Drug	CP-320650-01 [172079-28-6]; Up 200; 10uM; MCF7; HT_HG-U133A	CYP2C8 MYOC MR1 PIK3IP1 AEBP1 RAB3GAP2 AMPD1 PLAAT4 DDX60 SLC6A9	2.42e-04	195	295	10	4379_UP
Drug	Finasteride [98319-26-7]; Down 200; 10.8uM; PC3; HT_HG-U133A	MYO9B NOL6 ITGA7 FN1 SMURF1 PTPN21 GRM6 DENND3 CRY2 CAPN15	2.42e-04	195	295	10	4300_DN
Drug	Dextromethorphan hydrobromide monohydrate [6700-34-1]; Up 200; 10.8uM; MCF7; HT_HG-U133A	RELN MR1 ADARB1 RAB3GAP2 ATP11A DDX60 CRAT ARSD ENTPD1 KIF1C	2.42e-04	195	295	10	5401_UP
Drug	estradiol, USP; Up 200; 0.01uM; ssMCF7; HG-U133A	CEACAM5 MYO9B DYRK4 HMX1 PIK3IP1 AMPD1 DHX57 PMEL CRAT SYNGR1	2.52e-04	196	295	10	414_UP
Drug	Hexamethonium dibromide dihydrate [55-97-0]; Up 200; 10uM; HL60; HG-U133A	SLCO3A1 PIK3IP1 RAB3GAP2 NUP210 FN1 CRY2 GTF3C1 PCSK7 HTT SOS1	2.52e-04	196	295	10	1982_UP
Drug	Dipyridamole [58-32-2]; Down 200; 8uM; PC3; HT_HG-U133A	TPRA1 VWA8 CUL7 TINAGL1 C1orf105 DNAH3 NLGN1 PTPN21 DENND3 SLC9A2	2.52e-04	196	295	10	4656_DN
Drug	Hymecromone [90-33-5]; Up 200; 22.8uM; PC3; HT_HG-U133A	ADGRG1 POPDC2 PTPN21 GRM6 GRM8 ENTPD1 KCTD14 EPHA1 JHY KIF1C	2.52e-04	196	295	10	4623_UP
Drug	radicicol; Down 200; 0.1uM; MCF7; HG-U133A	CYP2C19 AHI1 CEACAM5 SAG DNAH3 PLAAT4 DSG3 SLC6A3 SLC9A2 PCSK7	2.52e-04	196	295	10	325_DN
Drug	Antazoline hydrochloride [2508-72-7]; Down 200; 13.2uM; MCF7; HT_HG-U133A	MYO9B BCR PHC3 MFNG PLXNA3 FN1 CRY2 SYNGR1 PCSK7 CAPN15	2.52e-04	196	295	10	6775_DN
Drug	Drofenine hydrochloride [548-66-3]; Up 200; 11.4uM; PC3; HT_HG-U133A	TPRA1 VWA8 MYO9A GPR39 SCG5 SMURF1 PTPN21 DENND3 SLC9A2 ENTPD1	2.52e-04	196	295	10	7129_UP
Drug	Estropipate [7280-37-7]; Down 200; 9.2uM; HL60; HT_HG-U133A	ZNF318 FRMD4B MFNG UTRN AMPD3 DDX60 NDST2 ARFGEF1 GATC AMBRA1	2.52e-04	196	295	10	2506_DN
Drug	Timolol maleate salt [26921-17-5]; Down 200; 9.2uM; MCF7; HT_HG-U133A	ADAM8 A4GALT NAALAD2 SMURF1 NLGN1 PTPN21 CRY2 ENTPD1 ZNF75D EPHA1	2.52e-04	196	295	10	6483_DN
Drug	Loxapine succinate [27833-64-3]; Down 200; 9uM; MCF7; HT_HG-U133A	VWA8 ATG2A PLEKHB1 CEP350 C1orf105 AP3M2 RNF31 AMBRA1 RFNG CRAT	2.52e-04	196	295	10	1516_DN
Disease	Disorder of eye	AHI1 MYOC CDH23 BMP4 SAG PCDH15 MERTK USH2A CNGA3 CYP4V2 RPGRIP1L GRM6 VCAN	2.06e-07	212	290	13	C0015397
Disease	Colorectal Carcinoma	ACACA CFTR APC2 PAK6 SLC12A5 BMP4 DLG3 UHRF2 AMPD1 DNAH3 FN1 NRCAM SCG5 POLE ARFGEF1 ABCB6 CUBN SFXN1 DCHS1 CTBP1 EDRF1 ACSL5 EPHA1	5.67e-07	702	290	23	C0009402
Disease	Schizophrenia	ARHGAP32 RELN AHI1 PDGFRB MYO9B SREBF1 BCL11A ADARB1 SLC12A5 PTPRA ASTN2 DLG3 ANK3 AMBRA1 NLGN1 PTPN21 GRM8 DICER1 SLC6A3 SLC6A9 TENM4 SYNGR1 SLIT3 TNXB	8.04e-06	883	290	24	C0036341
Disease	neuroimaging measurement	RELN DDAH1 KIF1B TRPS1 MR1 PAK6 BCR PLEKHB1 FRMD4B NEO1 CCM2 RAB3GAP2 ZSWIM4 LNX1 STRN3 AMPD3 SHROOM3 ANK3 KSR2 PTPN21 REV3L DENND3 VCAN SLC4A10 CDH11 HTT DNAH11	8.19e-06	1069	290	27	EFO_0004346
Disease	Partial Fetal Alcohol Syndrome	RPS6KA1 BPIFA1 ANK3	9.26e-06	5	290	3	C3661483
Disease	Alcohol Related Neurodevelopmental Disorder	RPS6KA1 BPIFA1 ANK3	9.26e-06	5	290	3	C0814154
Disease	Alcohol Related Birth Defect	RPS6KA1 BPIFA1 ANK3	1.84e-05	6	290	3	C3146244
Disease	Cerebellar Diseases	AHI1 RPGRIP1L PTF1A	3.19e-05	7	290	3	C0007760
Disease	atrial heart septal defect (is_implicated_in)	BMP4 TBX20 SOS1	3.19e-05	7	290	3	DOID:1882 (is_implicated_in)
Disease	frailty measurement	ANK3 NLGN1 REEP4 HTT	6.98e-05	23	290	4	EFO_0009885
Disease	bipolar I disorder	STARD9 PURB ASTN2 ANK3 MYO19 XPNPEP1 CUBN TENM4	8.09e-05	141	290	8	EFO_0009963
Disease	USHER SYNDROME, TYPE ID	CDH23 PCDH15	9.63e-05	2	290	2	601067
Disease	Adenosine monophosphate deaminase deficiency	AMPD1 AMPD3	9.63e-05	2	290	2	C2931781
Disease	Usher syndrome type 1D (is_implicated_in)	CDH23 PCDH15	9.63e-05	2	290	2	DOID:0110831 (is_implicated_in)
Disease	Usher syndrome, type 1D	CDH23 PCDH15	9.63e-05	2	290	2	C2931208
Disease	USHER SYNDROME, TYPE ID	CDH23 PCDH15	9.63e-05	2	290	2	C1832845
Disease	Usher syndrome type 1D	CDH23 PCDH15	9.63e-05	2	290	2	cv:C1832845
Disease	Muscle AMP deaminase deficiency	AMPD1 AMPD3	9.63e-05	2	290	2	C0268123
Disease	Teebi hypertelorism syndrome	SPECC1L CDH11	9.63e-05	2	290	2	cv:C0796179
Disease	Ciliopathies	AHI1 CFTR CDH23 PCDH15 USH2A RPGRIP1L DNAH11	1.11e-04	110	290	7	C4277690
Disease	thymol sulfate measurement	CYP2C19 CYP2C9 C2orf88	1.94e-04	12	290	3	EFO_0021170
Disease	Fetal Alcohol Spectrum Disorders	RPS6KA1 BPIFA1 ANK3	2.50e-04	13	290	3	C2985290
Disease	X-21258 measurement	CYP2C19 CYP2C9	2.87e-04	3	290	2	EFO_0800802
Disease	Bipolar Disorder	RELN INPP1 BCR ADARB1 STARD9 SORCS2 ASTN2 DLG3 ANK3 NLGN1 CRY2 SLC6A3 TENM4 SYNGR1	2.99e-04	477	290	14	C0005586
Disease	cortical surface area measurement	RELN DDAH1 MYO9B KIF1B SREBF1 BCR PLEKHB1 FRMD4B TINAGL1 NEO1 CSGALNACT2 RAB3GAP2 XRN1 ASTN2 ZSWIM4 LNX1 STRN3 SHROOM3 ANK3 SCG5 DENND3 VCAN SLC4A10 TNXB CDH11 DNAH11 SOS1	3.81e-04	1345	290	27	EFO_0010736
Disease	Colorectal Neoplasms	CFTR APC2 BMP4 NRCAM SCG5 POLE ABCB6 SFXN1 CTBP1 EPHA1	4.50e-04	277	290	10	C0009404
Disease	Intellectual Disability	AHI1 FRMPD4 PDGFRB APC2 QRICH1 BCL11A RTTN SPECC1L SLC6A3 RABL6 ENTPD1 SLC4A10 HTT	5.31e-04	447	290	13	C3714756
Disease	2-methylmalonylcarnitine (C4-DC) measurement	PTPRA CRAT	5.70e-04	4	290	2	EFO_0800250
Disease	Coloboma of lens	SALL2 ABCB6	5.70e-04	4	290	2	C0344516
Disease	Rhabdomyolysis	CYP2C8 AMPD1	5.70e-04	4	290	2	C0035410
Disease	Coloboma of eyelid	SALL2 ABCB6	5.70e-04	4	290	2	C0521573
Disease	Fetal Alcohol Syndrome	RPS6KA1 BPIFA1 ANK3	5.77e-04	17	290	3	C0015923
Disease	venous thromboembolism	RELN TSPOAP1 A4GALT ASTN2 ANK3 AMBRA1 ASH2L SFXN1 S1PR5 PIEZO2 PLXNA4 CMTM7 CDH11	6.92e-04	460	290	13	EFO_0004286
Disease	reticulocyte count	VWA8 MYO9B RPS6KA1 TRPS1 BCL11A SLC12A5 CCM2 PTPRA PURB A4GALT C1orf105 ATP11A HERC1 BSN AMPD3 C2orf88 PLEKHA4 GATC ABCB6 DENND3 SLC4A1 KIF1C	7.19e-04	1045	290	22	EFO_0007986
Disease	interleukin-6 measurement	SLCO3A1 SH2D7 PTF1A KSR2 GRM8 XIRP2	8.57e-04	112	290	6	EFO_0004810
Disease	Coloboma of optic disc	SALL2 ABCB6	9.44e-04	5	290	2	C0155299
Disease	Coloboma of choroid and retina	SALL2 ABCB6	9.44e-04	5	290	2	C4708599
Disease	pontocerebellar hypoplasia (implicated_via_orthology)	AMPD1 AMPD3	9.44e-04	5	290	2	DOID:0060264 (implicated_via_orthology)
Disease	Usher Syndrome, Type II	PCDH15 USH2A	9.44e-04	5	290	2	C1568249
Disease	USHER SYNDROME, TYPE IB (disorder)	CDH23 PCDH15	9.44e-04	5	290	2	C1848638
Disease	USHER SYNDROME, TYPE IA, FORMERLY	CDH23 PCDH15	9.44e-04	5	290	2	C1848639
Disease	USHER SYNDROME, TYPE I, FRENCH VARIETY, FORMERLY	CDH23 PCDH15	9.44e-04	5	290	2	C1848640
Disease	Hereditary macular coloboma	SALL2 ABCB6	9.44e-04	5	290	2	C1852767
Disease	Congenital coloboma of iris	SALL2 ABCB6	9.44e-04	5	290	2	C0266551
Disease	Usher syndrome, type 1A	CDH23 PCDH15	9.44e-04	5	290	2	C2931205
Disease	whole-brain volume	CUBN DNAH11	9.44e-04	5	290	2	EFO_0005089
Disease	Usher syndrome type 1	CDH23 PCDH15	9.44e-04	5	290	2	cv:C1568247
Disease	Retinal Degeneration	AHI1 RPGRIP1L ARG2	1.10e-03	21	290	3	C0035304
Disease	Primary Ciliary Dyskinesia	STK36 RPGRIP1L HYDIN DNAH11	1.17e-03	47	290	4	C4551720
Disease	Autistic Disorder	RELN AHI1 VWA8 INPP1 CUL7 ASTN2 NRCAM NLGN1 GRM8	1.18e-03	261	290	9	C0004352
Disease	ocular hypertension, response to triamcinolone acetonide	VWA8 CDH23 VARS1 TEX14	1.37e-03	49	290	4	EFO_0006954, EFO_1001069
Disease	Prolactinoma	CDH23 BMP4	1.41e-03	6	290	2	C0033375
Disease	Usher Syndrome, Type I	CDH23 PCDH15	1.41e-03	6	290	2	C1568247
Disease	Nonsyndromic Hearing Loss and Deafness, Autosomal Recessive	CDH23 PTPRQ PCDH15 ESPN	1.59e-03	51	290	4	cv:CN043650
Disease	coronary artery disease	MYO9B RPS6KA1 CFTR SREBF1 QRICH1 CCM2 GPR149 NUP210 SHOC1 N4BP2L2 ASTN2 MERTK BSN TBX20 LNX1 DAGLB SHROOM3 FN1 NOA1 KSR2 SPECC1L EPG5 TNXB	1.76e-03	1194	290	23	EFO_0001645
Disease	pallidum volume change measurement, age at assessment	SORCS2 GRM8 SLIT3	1.84e-03	25	290	3	EFO_0008007, EFO_0021494
Disease	obsolete_red blood cell distribution width	AHI1 MYO9B ENTR1 CDH23 BCL11A ITFG1 PIK3IP1 NEO1 PTPRA NUP210 A4GALT C1orf105 ATP11A HERC1 DAGLB SCG5 MYO19 ABCB6 MRPL28 CRAT GBA2 SLC4A1 EPG5 RNF123 PRKAG1	1.86e-03	1347	290	25	EFO_0005192
Disease	Hereditary retinal dystrophy	CDH23 PCDH15	1.96e-03	7	290	2	C0154860
Disease	Usher syndrome	CDH23 PCDH15	1.96e-03	7	290	2	cv:C0271097
Disease	tumor necrosis factor ligand superfamily member 6, soluble form measurement	BSN RNF123	1.96e-03	7	290	2	EFO_0020797
Disease	atrioventricular septal defect (implicated_via_orthology)	BMP4 DNAH11	1.96e-03	7	290	2	DOID:0050651 (implicated_via_orthology)
Disease	IGFBP-3 measurement	PAK6 SORCS2 UNC79 MAPK15	1.96e-03	54	290	4	EFO_0004626
Disease	myeloperoxidase measurement	ATP6V1B2 TSPOAP1 TNXB	2.07e-03	26	290	3	EFO_0005243
Disease	DNA methylation	DDAH1 SLCO3A1 PXDNL LNX1 USH2A DNHD1 VPS72 GRM8 TENM4 ENTPD1 PLXNA4 DCHS1 CDH11 JHY DNAH11	2.30e-03	656	290	15	GO_0006306
Disease	glycine measurement	VWA8 TRPS1 PTH2R UHRF2 GRM8 TENM4	2.40e-03	137	290	6	EFO_0009767
Disease	S-warfarin to R-warfarin ratio measurement	CYP2C19 CYP2C8 CYP2C9 MTHFD2L ENTPD1	2.50e-03	95	290	5	EFO_0803331
Disease	free cholesterol change measurement, high density lipoprotein cholesterol measurement	FAM13C SLIT3	2.59e-03	8	290	2	EFO_0004612, EFO_0020905
Disease	procollagen galactosyltransferase 1 measurement	DAGLB COLGALT1	2.59e-03	8	290	2	EFO_0801922
Disease	renal tubular acidosis (implicated_via_orthology)	ATP6V1B2 SLC4A1	2.59e-03	8	290	2	DOID:14219 (implicated_via_orthology)
Disease	Tinnitus, wellbeing measurement	CDH23 ASTN2 PTPN21 GRM8 CAPN15	2.61e-03	96	290	5	EFO_0007869, HP_0000360
Disease	attention deficit hyperactivity disorder, substance abuse, antisocial behaviour measurement	NOL6 CDH23 BCL11A PLEKHB1 RAB3GAP2 PCDH15 GGACT HERC1 USH2A UNC79 UTRN NLGN1 REV3L GRM8 TENM4 PLXNA4 CTBP1	2.62e-03	801	290	17	EFO_0003888, EFO_0007052, MONDO_0002491
Disease	HbA1c measurement	MYO9B SLCO3A1 BCL11A AEBP1 A4GALT ATP11A BSN AMPD3 NLGN1 SLC4A1 RNF123 PRKAG1 SEZ6 KIF1C SOS1	3.00e-03	675	290	15	EFO_0004541
Disease	gastroesophageal reflux disease	ADARB1 UNC79 CNGA4 GRM8 VCAN	3.26e-03	101	290	5	EFO_0003948
Disease	glioblastoma (implicated_via_orthology)	POLE BAG3	3.31e-03	9	290	2	DOID:3068 (implicated_via_orthology)
Disease	platelet component distribution width	AHI1 MYO9B PURB A4GALT C1orf105 N4BP2L2 DLG3 HERC1 PEAR1 RTTN CUBN NCOR2 METTL13 DDHD1 ENTPD1 TNXB	3.51e-03	755	290	16	EFO_0007984
Disease	hypertension	MYO9B ZNF318 PHC3 SORCS2 TBX20 AMPD3 GPR39 NCOR2 TNXB	3.54e-03	307	290	9	EFO_0000537
Disease	Retinitis Pigmentosa	AHI1 SAG MERTK USH2A CYP4V2	3.69e-03	104	290	5	C0035334
Disease	autism spectrum disorder (implicated_via_orthology)	ARHGAP32 PDGFRB NRCAM NDST2 NLGN1 SLC6A3	4.01e-03	152	290	6	DOID:0060041 (implicated_via_orthology)
Disease	membranoproliferative glomerulonephritis (biomarker_via_orthology)	MYOC FN1	4.11e-03	10	290	2	DOID:2920 (biomarker_via_orthology)
Disease	unipolar depression, bipolar disorder	PXDNL STARD9 PURB ASTN2 ANK3 TENM4	4.55e-03	156	290	6	EFO_0003761, MONDO_0004985
Disease	hippocampus molecular layer volume	ASTN2 VCAN SLC4A10	4.87e-03	35	290	3	EFO_0009397
Disease	Machado-Joseph disease, age at onset	INPP1 ATP11A	4.99e-03	11	290	2	EFO_0004847, MONDO_0007182
Disease	invasive ductal carcinoma (is_implicated_in)	ADAM28 UBR5	4.99e-03	11	290	2	DOID:3008 (is_implicated_in)
Disease	X-11308 measurement	CYP2C19 CYP2C9	4.99e-03	11	290	2	EFO_0800693
Disease	Ashkenazi Jewish disorders	CFTR ASPA	4.99e-03	11	290	2	cv:CN118946
Disease	Manic Disorder	RELN STARD9 ANK3 TENM4	5.30e-03	71	290	4	C0024713
Disease	R-6-hydroxywarfarin measurement	TRPS1 STRN3 SHROOM3 DDX60 NCOR2	5.45e-03	114	290	5	EFO_0803327
Disease	bipolar disorder, body mass index	CDH23 RPGRIP1L TRIM42 GRM8	5.57e-03	72	290	4	EFO_0004340, MONDO_0004985
Disease	Night blindness, congenital stationary, type 1	SAG GRM6	5.95e-03	12	290	2	C3501847
Disease	rotator cuff tear, shoulder impingement syndrome	FRMPD4 ASTN2	5.95e-03	12	290	2	EFO_1001178, EFO_1001250
Disease	Night Blindness, Congenital Stationary, Type 1A	SAG GRM6	5.95e-03	12	290	2	C3495587
Disease	nervous system disease (implicated_via_orthology)	KIF1B KIF1C	5.95e-03	12	290	2	DOID:863 (implicated_via_orthology)
Disease	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 2B (disorder)	SAG GRM6	5.95e-03	12	290	2	C1864877
Disease	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 1B	SAG GRM6	5.95e-03	12	290	2	C1850362
Disease	X-Linked Csnb	SAG GRM6	5.95e-03	12	290	2	C3711543
Disease	NIGHT BLINDNESS, CONGENITAL STATIONARY, TYPE 2A	SAG GRM6	5.95e-03	12	290	2	C1848172
Disease	creatinine measurement, glomerular filtration rate	DDX1 BMP4 ASTN2 SHROOM3 MICALL2	6.07e-03	117	290	5	EFO_0004518, EFO_0005208
Disease	sleep quality	MYO9B TRPS1 PIGZ SLC9A2 TENM4	6.29e-03	118	290	5	EFO_0005272
Disease	Amphetamine-Related Disorders	ASTN2 CUBN SLC6A3 SLC6A9	6.43e-03	75	290	4	C0236733
Disease	Amphetamine Abuse	ASTN2 CUBN SLC6A3 SLC6A9	6.43e-03	75	290	4	C0236807

Protein segments in the cluster

Peptide	Gene	Start	Entry
VPPITRALLYEGISH	ATP6V1FNB	91	A0A1B0GUX0
REAGPVVHQSPTVLY	nan	26	A4D1N5
YVPNFLSEPGLHTRA	AEN	216	Q8WTP8
IVDYVSDETQRHPPT	EPG5	1676	Q9HCE0
RPRSPGANLTYELHV	EPHA1	471	P21709
HRLPVIDPESGNTLY	PRKAG1	151	P54619
PDSEPLYHAVIARVG	ARSD	531	P51689
EIPGYLPADTVHLAV	LRG1	61	P02750
TREGGHIVYDQLPTP	ARG2	326	P78540
EPSAHLDPVTYQIIR	CFTR	1371	P13569
DPAVVHPELNGAAYR	CTBP1	366	Q13363
PSQHRTEIELFPYSG	VCAN	646	P13611
HPVYVRRAATENIPV	CDC73	71	Q6P1J9
PEAPHIDYTQLGRAA	SLC4A1	271	P02730
PEELPRLLSATYAVH	A4GALT	301	Q9NPC4
QRYFIEPLSPIHRDG	ADAM28	136	Q9UKQ2
DGVHEITSRDSPVYP	AHI1	321	Q8N157
QRRHQDGLPYIDDSP	BCR	446	P11274
RIHLVPSLNPDGYEV	AEBP1	661	Q8IUX7
LRYLPPQTVDHISQE	ARFGEF1	246	Q9Y6D6
VDHSDPVILNVLYGP	CEACAM5	401	P06731
LHSGGPVLPYVRESV	FAM220A	76	Q7Z4H9
QRYSDLVPTGVPHAV	CYP2C8	356	P10632
PNYGEIPVQEHLLRT	SPECC1L	906	Q69YQ0
PEVDLYGTVQPHTLI	DNAH11	2581	Q96DT5
APGLRPQSYTLQVHE	ABCB6	206	Q9NP58
DPVYIHLAERLGTPE	ACACA	2141	Q13085
YEHAAAEGPPIVTLL	CRAT	341	P43155
LGIARPRVEYPAHQA	SCG5	51	P05408
IPGYLNPSSRTEILH	CCM2	76	Q9BSQ5
HAEPRLSIYGRSPDE	AMPD1	421	P23109
EIYFHGEPIPVTVTV	SAG	216	P10523
ELPGLNSTHYVVFPR	SLC7A4	596	O43246
VEITHLYPSGLSPQE	DNHD1	2026	Q96M86
LPSHLGLHPERVSYV	ADAM8	46	P78325
PEIPIDGTELSHYRQ	AMBRA1	211	Q9C0C7
YEDPRQHSPGVLTDL	DICER1	1721	Q9UPY3
GQSVHQLLPPTYRDV	DHX29	451	Q7Z478
PQAVDVLLYTPGHLD	DENND3	891	A2RUS2
EEQIHSTGLEYPERP	BMP4	96	P12644
QYQLLTVPEHSPRGT	CDH23	2731	Q9H251
VTQLHPGPIVVRDGY	ATG2A	1381	Q2TAZ0
EIHYIPSVLLGPQAR	ASTN2	251	O75129
ITSQYLGHPRADTAP	AMPD3	176	Q01432
LYHVETEVDGRRSPP	ASH2L	611	Q9UBL3
TVLQYRPVHIDPISR	RBM12B	346	Q8IXT5
PHRAVEYLLTGIPGS	RAD23A	191	P54725
RVTPLGYVLPSHVTE	QRICH1	591	Q2TAL8
HRLQGRPFVEEYIPT	RABL6	61	Q3YEC7
PSETLAYQHLPVRIF	TSPOAP1	1616	O95153
SQDVYLGRPSLDHPI	RFNG	166	Q9Y644
IIHIPSLGYSQPVRE	IQCH	451	Q86VS3
HPLRYPSIITDQFVA	OR56A4	131	Q8NGH8
EPPGHVLAVYSSRLV	CAPN15	926	O75808
IPPDGNFRLLSYHVS	AP3M2	251	P53677
PEYHVSVRENVPVGT	PCDHGA4	276	Q9Y5G9
RTYEIPRHPGVTEQN	RAB3GAP2	191	Q9H2M9
RVSPEEVTIYNHPGI	NUP210	896	Q8TEM1
LRAQEQIPPGVYHIS	DSG3	551	P32926
SIPDPLQHGNYLVTE	DSG3	921	P32926
ILPSDHYVLTVPNLR	ANOS1	611	P23352
YPVQIARTHTDVGLL	NCOR2	26	Q9Y618
VHYAPTIRALQDPTE	NPHS1	736	O60500
QVPEHTAFGTRYPLE	DCHS1	151	Q96JQ0
VYAQDRGSPPQLTHV	DCHS1	1721	Q96JQ0
HYRVAVTEDLPPGST	DCHS1	2486	Q96JQ0
NPETGLDLPQLVYHV	INPP1	341	P49441
QSPQSERTDPHGLYL	PAK6	131	Q9NQU5
TEYPLVNVPSHRGLT	GPR39	176	O43194
SPFLTPVQGLDRHYL	HELT	206	A6NFD8
NSHRVVEEYFVAPPG	GATC	106	O43716
RGESHPEQISYPVRV	JHY	281	Q6NUN7
HVLEATYGINIITPR	LSG1	481	Q9H089
YHQRILDIVPPTFSA	NCBP1	461	Q09161
ELQTTPVVRGLHPEY	RPGRIP1L	641	Q68CZ1
PGLEPFSHYTLNVRV	NRCAM	916	Q92823
SDPIYIEVQGLPHFT	MERTK	186	Q12866
LSREPSFIVVHYAGP	MYO19	521	Q96H55
SEPLEPSYIVGHVAS	EDRF1	266	Q3B7T1
RPRAHEGVQLSVPEY	MAPK15	321	Q8TD08
RLYQVTVHVPPTIAD	HMCN2	3841	Q8NDA2
LEPTGEYIPAVVDHT	KIF1B	1261	O60333
PGAPVYTHVDRLTVD	KSR2	216	Q6VAB6
FPSLRLLVEHYPEGV	ESPN	151	B1AK53
TVPPQYGALREVSIH	HERC1	4381	Q15751
RLPHNATTGYEELLP	BSN	896	Q9UPA5
LEIGYQAHLPPESLS	BSN	2766	Q9UPA5
RIYLESEHGSPLTPR	BCL11A	196	Q9H165
PLSSPLNGVHDRAYV	GLB1	431	P16278
TDHIERYGFPPDLTL	DDX60	1011	Q8IY21
TSPLEVLPGYETHLE	C9orf131	311	Q5VYM1
IHGVPYVINVTLPDE	DDX1	581	Q92499
GQTDHPQPILDRYTE	ITGAE	796	P38570
GETVTSPVRLHPDYL	MICALL2	721	Q8IY33
YLFVQPAGHRPALEV	PCSK7	96	Q16549
TYAVRVLFPGIEAHP	PLXNA3	1301	P51805
DHPVLRDLEVPGYRQ	PLXNA4	1331	Q9HCM2
LYTPILHTQARSPEG	FAT2	2186	Q9NYQ8
LDVGDSSQIHPYQLP	LRRC36	311	Q1X8D7
SGTYEQPSPLIHDRD	PEAR1	976	Q5VY43
PGLHAYPDELIRQRV	CUL7	16	Q14999
RHDDRPQVLSYAVPV	CUL7	1636	Q14999
TGLPYELQAVTEAPH	FAM214B	516	Q7L5A3
HYAFETSPRPIDVLG	FAM217B	261	Q9NTX9
AQRLVRVPVLYHESP	HMX1	276	Q9NP08
VQGAHPVLRYTEVFP	NOL6	686	Q9H6R4
PTLGDVESLVPLYLH	MOSPD1	176	Q9UJG1
HILPRPLESTGAVVY	MYOC	316	Q99972
LRVREHPILGPYVQD	KIF1C	166	O43896
PRLYHLIPDGEITSI	LNX1	261	Q8TBB1
TLEPYPLVIAGEHNI	GGACT	36	Q9BVM4
LPAHDRQYVRSVAPG	GDPD4	366	Q6W3E5
RYFHIPIGNLPEDIS	POLE	1651	Q07864
DIQPARYHIAFGPVI	NLGN1	386	Q8N2Q7
HLYREDQTSPAPGLR	PIK3IP1	31	Q96FE7
IPRSQHQETPVYLGA	ENTPD1	116	P49961
IFSPHEPILEGSRSY	ADARB1	456	P78563
DAYGTVQLRPLHRLP	ARHGAP32	1671	A7KAX9
VDPPHIIIDYGEQRT	GRM8	716	O00222
HILRQLPITYPSAEE	PHC3	851	Q8NDX5
RIVYDIPTGIQGPEH	DTX1	506	Q86Y01
GQRSHLPYDVTPEQA	IQGAP3	1091	Q86VI3
THLELIGNYLETLPP	LRRC8B	751	Q6P9F7
RAPDQPGEGVLLHYS	RELN	786	P78509
LSYHEPRIISVELPG	RELN	816	P78509
LYGLDPRHAVPSATN	HPDL	66	Q96IR7
EYLVRVHVPPNIAGT	HMCN1	3611	Q96RW7
PSGHVERYQVDLVPD	PTPRQ	31	Q9UMZ3
DAFEGLRSHIPTLPY	PTF1A	181	Q7RTS3
PAALVYSQPEIREHA	PTPN21	486	Q16825
PSTLNYLVHLQERPV	PIK3C2B	481	O00750
EPPRLHSNYQEISRG	GPR149	221	Q86SP6
HLGAPSPRYLELDLT	PCDHAC2	81	Q9Y5I4
LRLAQSEPYTTIHQP	NPC1L1	16	Q9UHC9
VLHPGEIPRFTQEEY	PCDH15	1026	Q96QU1
IIQRGRDHGIPPYVD	PXDNL	1141	A1KZ92
VVESIGHPTLPYRDN	CUBN	2346	O60494
EVDRVPHNPYATLRL	FRMD4B	861	Q9Y2L6
RSPEVILGHPYDVAI	DYRK4	271	Q9NR20
GLLTQHGIPYTRPTE	GNPTG	261	Q9UJJ9
HGIPYTRPTETSNLE	GNPTG	266	Q9UJJ9
SPTYQHVPLLEGASR	APC2	996	O95996
PGTVITEHYGPTNIR	ASPHD2	276	Q6ICH7
YLHGDLIVIRTPVPG	CSGALNACT2	466	Q8N6G5
LEVVAAPGSPYHRLL	HTT	3116	P42858
PQIDSLDLRGEVHYP	HYDIN	1151	Q4G0P3
RDPAVHPAGILYTLL	HYDIN	3306	Q4G0P3
QEGPLYRTEGSHITI	IGSF3	26	O75054
GALEHDPSSIYLRIP	HEATR5B	751	Q9P2D3
LGARPPHSVIDYEEQ	GRM6	716	O15303
VQSPDGHRLYVTIPL	BPIFA1	121	Q9NP55
QRYIDLIPTSLPHAV	CYP2C19	356	P33261
PGEQRHLPRIVSYIE	SDR42E1	191	Q8WUS8
IGVDYPRPIVNHAET	CRY2	481	Q49AN0
YLRNLPITAHPEVFG	DNAH3	3786	Q8TD57
RQITPILPHDYQDSS	GBA2	251	Q9HCG7
ILPHDYQDSSLPVGV	GBA2	256	Q9HCG7
YPPGRIIHLQEEGAS	DAGLB	591	Q8NCG7
GAYLPSAIEQTHPER	ENTR1	186	Q96C92
GYRVDVIPVNLPGEH	FN1	936	P02751
EVTLLVGPRYGISHV	FRMPD4	436	Q14CM0
LTPDERLTPLGYHLA	DHX57	1046	Q6P158
SPQEAPHVQYERLGS	CNTFR	26	P26992
PHVQYERLGSDVTLP	CNTFR	31	P26992
YTGPDPVLVGRLHSD	CDH11	66	P55287
EPLVSYREIHGAPSN	CEP350	126	Q5VT06
NYGPIILAVHRTPEG	ADGRG1	541	Q9Y653
ILAVHRTPEGVIYPS	ADGRG1	546	Q9Y653
PLYDTLGPEAIVHIV	ACSL5	161	Q9ULC5
LEPVYQLTSRGDHEL	ANGPTL6	331	Q8NI99
HVIRSYDPSAGDVPQ	ANK3	2171	Q12955
GTEAVIIPYALHRDP	CYP4V2	416	Q6ZWL3
RQEIHYARPVIILGP	DLG3	621	Q92796
PDVPQLGNIDVIHSY	MS4A4E	16	Q96PG1
SYPHIIRLLSQEEGV	MAPKBP1	926	O60336
SERTGISYVHIPPLR	ITIH6	181	Q6UXX5
HGILRDFYSPLVPDS	CLDN2	141	P57739
LLAGYTHERIIQPPL	EFHB	116	Q8N7U6
PQRHSLSEITYLGQP	IL22RA1	316	Q8N6P7
LPDSLHYSGVRALDP	ITGA7	761	Q13683
IPHGPVVGSTRRLYE	EMD	21	P50402
PAARHRYEVVTELGP	DDHD1	151	Q8NEL9
IYGPEEQRHLPRVAG	SDR42E2	211	A6NKP2
QRYIDLLPTSLPHAV	CYP2C9	356	P11712
DTGEPRYTLHVVDSP	METTL13	276	Q8N6R0
EEYGFLPVPLRAHST	COLGALT1	286	Q8NBJ5
GEPRHDSLLPVDSYQ	HOXB13	156	Q92826
LPRGYISIPVIHEQN	BAG3	201	O95817
VPGHVLQRPSYLTRI	BLID	81	Q8IZY5
LRPAPVSEVIVLHYN	S1PR5	6	Q9H228
PVPEHLDYVITSSGL	SALL2	436	Q9Y467
GHVLLHRTPEEYPES	DDAH1	231	O94760
LHLRGYTPEGTVLTV	NOA1	641	Q8NC60
HYDALILVTPGAPTE	IRGQ	296	Q8WZA9
YVGRPSLNRPIHASE	MFNG	166	O00587
IEHYAQLGPSSPEQL	PURB	91	Q96QR8
HVANPRGAVTPEYTV	KRTCAP3	46	Q53RY4
HRSRTLQVVFEAYPP	PDGFRB	331	P09619
RVHLTPVEGVPDSDY	PTPRA	281	P18433
PPLELGYRVTAEDLH	nan	176	A6NNC1
LYLEDQVSHRRPPIG	REEP4	171	Q9H6H4
ARYALLRLEEGPPHT	SLC12A5	676	Q9H2X9
VPEFISVGYVDSHPI	MR1	41	Q95460
VTDAPHFYGLPSLER	RTTN	1251	Q86VV8
GTDRITAPTHVPLQY	SARS2	486	Q9NP81
EVVLYSGARPLSHQP	VARS1	206	P26640
PPLIQNGDILSYEIH	USH2A	2746	O75445
PRYAEIVHLTLPDGT	ATP6V1B2	66	P21281
ITHPIPDLTGYITEG	ATP6V1B2	361	P21281
HPRLGYLPVQTVLEG	UTRN	3146	P46939
ELSRPQQYTIPGILH	STRN3	56	Q13033
LDVEPIYTFRAHIGP	STRN3	521	Q13033
GIQTTYRPDPQLRLH	TRIM42	456	Q8IWZ5
HEIYTVLNPGEVLPT	TINAGL1	191	Q9GZM7
ELVLHYSSRPLPVQG	SHD	311	Q96IW2
YSSRPLPVQGAEHLA	SHD	316	Q96IW2
TESPRVQRYGLHPDV	TEX14	526	Q8IWB6
NVYLGLTSEHPRETP	TEX14	541	Q8IWB6
VHDYRQGIVPPGLTE	SFXN1	51	Q9H9B4
GLSDPVAYITLDPRH	SSPOP	676	A2VEC9
TLPHYEEGSLPILNT	TLR10	176	Q9BXR5
ATPVQPLGVSYIDDH	SLCO3A1	191	Q9UIG8
PAEGVPAYISLHRLL	TCAF2	451	A6NFQ2
PYLPTSEGHRERVLS	PLEKHA4	661	Q9H4M7
DHEYQPRPVEVIISS	PLAAT4	81	Q9UL19
GEGIPLYESAVTRPH	NEO1	816	Q92859
LTLTGEPIRHRYESP	SORCS2	831	Q96PQ0
VPIYDGNALPHATLR	POTEJ	826	P0CG39
AQHASGEVEEPPRYL	POLR2B	71	P30876
LTVPRIQEPHSQYSV	SHOC1	326	Q5VXU9
DLGSHLDRQVSYPRP	SHROOM3	711	Q8TF72
IETPYGLLHVVIRGS	NDRG4	11	Q9ULP0
RLDLEGNEYPIHSTP	ARHGAP5	1011	Q13017
VTRPVPLEHYLFTGN	SKIV2L	481	Q15477
PEHQEPRTLDTTYGE	STARD9	2781	Q9P2P6
LYHITDGDNPLLSPR	FAM13C	226	Q8NE31
DYLRTGQVPTQHIPE	KCTD14	91	Q9BQ13
GQVPTQHIPEVYREA	KCTD14	96	Q9BQ13
SRALVVTHTYLEPGP	PMEL	271	P40967
SPVYRLDHTFEQIPS	SOS1	881	Q07889
HQSPELPEGYEQRTT	SMURF1	231	Q9HCE7
YRPLRSLLGHPENSV	STK36	1111	Q9NRP7
LVLLFVYGEPVTRPH	SREBF1	561	P36956
TELYRSLFGQLHPPD	AATF	541	Q9NY61
ESIHYRLPILGPRTA	C1orf105	136	O95561
YPRDENGEIAAIIHP	ASPA	231	P45381
SVYTHFLPQRGRPEV	ANGEL1	576	Q9UNK9
PLEGLLDLSYPRTHA	CMTM7	31	Q96FZ5
EHRYSAAGVSLLEPP	CHPT1	31	Q8WUD6
VYPNISIPEHGRLSR	CNGA3	336	Q16281
DVVYVRLGPHTPTLR	CNGA4	126	Q8IV77
VDSRTIYVGHREPPP	ATP11A	21	P98196
LETATERYLHVRPQP	RNF31	1026	Q96EP0
ERYLHVRPQPLAGED	RNF31	1031	Q96EP0
IPSHLPEYVTDLRLN	SLIT3	526	O75094
VPPRLSEHTQRYEAA	XIRP2	3126	A4UGR9
IAHYQPETDRAPRGL	RINL	506	Q6ZS11
TRECTIVPSNHYGPI	UHRF2	436	Q96PU4
PLLSVYGTQDPRHFL	ZNF750	271	Q32MQ0
YVAPEVLLRQGHGPE	PLK3	226	Q9H4B4
IRSEALPASYHPDLG	TIGD3	226	Q6B0B8
PNVEAAHLARPIYGL	TRPS1	831	Q9UHF7
VHLPQPYAVARREGL	TPRA1	306	Q86W33
IIPSGDAHQSEYIAP	XPNPEP1	31	Q9NQW7
GAIIHYAPVPETNRT	XPNPEP1	391	Q9NQW7
YIPSGPITTIHENEV	WWC2	496	Q6AWC2
DTTLQPGYPHDLITL	MMP16	416	P51512
PPDLLYQVRHDITVS	REV3L	2656	O60673
LGHQYVRSESDFPPV	SPEG	2571	Q15772
SRLPVFTLDYPHVQI	SLC9A2	66	Q9UBY0
HPDARVLGPGVSYVV	SHC2	141	P98077
RYHVPVVVVPEGSAS	RPN2	266	P04844
PYAGPGVTHVIVRED	PLEKHB1	196	Q9UF11
RLPGLESVDHYPILV	RNF123	1136	Q5XPI4
VVVSIVTFRPPHYGA	SLC6A3	536	Q01959
TVQLPLEGHYRDDPS	SLC4A10	1066	Q6U841
LREVSVPGLDPAHRY	TNXB	1826	P22105
TPGSAVDYPLHDLVL	TNXB	3891	P22105
DNTIYRLAHPEGSLP	PIEZO2	826	Q9H5I5
LTIHQRIHTGERPYP	ZNF775	461	Q96BV0
YRPLEQQHGVIPDRD	XRN1	1086	Q8IZH2
LTPIYHPNIDSAGRI	UBE2T	71	Q9NPD8
GIQVTSTEEYPHLRP	NDST2	451	P52849
EEVTPPHGTLYRTDI	TENM4	86	Q6N022
PALLEHRTGRYAPTI	SLC6A9	656	P48067
DPYTLVRQPHTILRV	SYNGR1	16	O43759
YDAITRGLHQTIVDP	SH2D7	151	A6NKC9
RRPAYGDVTVTSLHP	SEZ6	361	Q53EL9
TIVPHGYTEVANIPV	VPS13C	2491	Q709C8
DIRLPSLYHVLGPTA	POPDC2	261	Q9HBU9
GHYLRSLEEERTPTP	MRPL28	26	Q13084
VPGLEYLEQVVHAPV	PIGZ	436	Q86VD9
SLEQPYLTHRLSGPV	WDR46	436	O15213
IASRQPDSHITLPGY	PTH2R	481	P49190
LLYFPRGTIHQADTP	RIOX2	231	Q8IUF8
PPGTNTVILEYAHRL	C2orf88	51	Q9BSF0
IILVGDNPASHTYVR	MTHFD2L	86	Q9H903
RYHEATGPLETISQL	ZNF75D	56	P51815
PYSGLGEIIHRESVP	ZSWIM6	751	Q9HCJ5
SLVQLQRVHPGERPY	ZNF416	256	Q9BWM5
TLTHYVRPINAEPVF	TASOR2	1666	Q5VWN6
ARLYVHPDSPFTGEQ	TBX20	181	Q9UMR3
HEFTVGVYEPLPQLS	VSIG10L	291	Q86VR7
IITYHSVTVPLVGEP	VPS72	211	Q15906
PTQQEPALHRVGVYL	TRIM4	436	Q9C037
TEIPIPITLHIGDYN	ITFG1	326	Q8TB96
LATHPGISFYEEPRE	GTF3C1	51	Q12789
GPALINIQEYPIERH	VWA8	1076	A3KMH1
YINEVRVIPPGVRAH	VIRMA	36	Q69YN4
VYSTFLLHDPRPVGN	ZP3	111	P21754
SEPGYSLHRPEEVSV	ZNF318	361	Q5VUA4
YQPRLHIVEVNDGEP	TBX21	266	Q9UL17
ASSRIGHLLPEEQVY	UBR5	1356	O95071
RVLHNIYPVPSGTDI	UNC79	21	Q9P2D8
SPGEPERLYHVSISF	ZSWIM4	131	Q9H7M6
PSEEIEILLRYGQHP	RPS6KA1	456	Q15418
VQEPPLDYSFRSIHV	LRRC51	11	Q96E66
RIPVHPIGYNDAEIL	NAALAD2	281	Q9Y3Q0
PVTIIDVRGHSYLQE	N4BP2L2	56	Q92802
HTLRIYPGAISEGTI	MYO9A	16	B2RTY4
ARRPDQIHSVYITPG	MYO9B	2101	Q13459